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1 Summary
Stem cells with the particular potential to self renew and to differentiate into multiple cell
lineages are fascinating cell types for basic and applied research. Pluripotent embryonic stem
(ES) cells are derived from the inner cell mass (ICM) of preimplantation embryos. Upon
differentiation ES cells can give rise to cells of ecto-, meso- and endoderm including germ
cells. In contrast, multipotent adult stem cells are more restricted in their differentiation out-
comes, they differentiate into cells of their tissue of origin. For example, hematopoietic stem
cells (HSCs) that reside in hemogenic tissues such as the bone marrow (BM) differentiate
into hemato-/lymphoid cell lineages. Upon differentiation of stem cells not the genome, but
the epigenetic regulation changes. Differentiation-associated epigenetic changes generate cell
types with distinct phenotypes and functions. For stem cell-based therapies it is important
to deeper understand the relation between epigenome and cellular function.
In the scope of this thesis I aimed to analyze cultures of differentiating stem cells with respect
to gene expression, chromatin regulation and differentiation potential.
For the analysis of global histone modification levels, which represent one mechanism for
epigenetic regulation, flow cytometric protocols were established that allow single cell mea-
surements. By applying this methodology decreased histone acetylation levels were shown
in differentiated ES cell populations. In contrast, comparable histone acetylation levels were
observed in differentiated and undifferentiated BM cells.
In addition, I investigated effects of the histone deacetylase (HDAC) inhibitor trichostatin A
(TSA) on murine BM cells, comprising also HSCs. Upon TSA treatment the frequency of
cells with in vitro and in vivo hematopoietic activity was increased, while lineage committed
cells underwent apoptosis.
Next, the loss of pluripotency was assessed in differentiating ES cell cultures. Using short-term
in vitro differentiation protocols marker-based analyses and functional assays were performed.
Functionally pluripotency was diminished after 2 days of differentiation as assessed by colony
formation, embryoid body (EB) formation and cardiomyogenic differentiation approaches. In
contrast, pluripotency marker expression was reduced at later time points. Further, the ap-
plication of distinct differentiation systems (aggregation EB, clonal EB or monolayer (ML)
culture) had an impact on the progression and homogeneity of differentiation cultures. To
further study the end of pluripotency, differentiated ES cells were placed under ES cell cul-
ture conditions. The data suggest that 3 days differentiated ES cells had passed a point of
no return and failed to regain Oct4-eGFP expression and that HDAC inhibitor treatment
selectively killed differentiated ES cells.
Finally, I aimed to study the effect of EED - a core subunit of the histone methylating Poly-
comb repressive complex 2 (PRC2) - on ES cell chromatin and function. ES cells lacking EED
showed loss of histone H3 lysine 27 trimethylation (H3K27me3) accompanied by increased
histone acetylation and reduced H3K9me3 levels. Despite typical ES cell morphology and
pluripotency marker expression, EED knockout (KO) ES cells exhibited altered nuclear hete-
rochromatin organization, delayed chromatin mobility and a failure in proper differentiation.
Conclusively, my data provide insights into the epigenetic regulation of stem cells. Particu-
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larly, the results suggest that HDAC inhibitor treatment was detrimental for differentiated
BM as well as for differentiated ES cells and that ES cells after 3 days of differentiation had
lost pluripotency. Further, the data demonstrate that EED KO ES cells self renewed, exhib-
ited morphology and pluripotency marker expression similar to wild type ES cells, but failed
to differentiate. This indicates an important role of EED not only for undifferentiated but
also for differentiating ES cells.
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2 Zusammenfassung
Stammzellen mit ihrer besonderen Fa¨higkeit sich selbst zu erneuern und zu differenzieren
stellen einen faszinierenden Zelltyp fu¨r Grundlagenforschung und angewandte Wissenschaften
dar. Pluripotente embryonale Stammzellen (ES Zellen), die aus Zellen der inneren Zellmas-
se von Pra¨implantationsembryonen etabliert werden, ko¨nnen ekto-, meso- und endoderma-
le Zelltypen sowie Keimzellen hervorbringen. Im Gegensatz dazu sind multipotente adulte
Stammzellen in ihrem Entwicklungspotential eingeschra¨nkt, sie differenzieren sich zu allen
Zelltypen ihres Gewebes. Zum Beispiel ha¨matopoetische Stammzellen (HSZs), die sich in
Blut-bildenden Geweben wie dem Knochenmark befinden, vermo¨gen sich in alle Blutzellen zu
differenzieren. Wa¨hrend der Differenzierung von Stammzellen a¨ndert sich nicht deren Genom,
sondern ihre epigenetische Regulation. Durch epigenetische Mechanismen werden Zelltypen
mit verschiedensten Pha¨notypen und Funktionen generiert. Fu¨r Stammzelltherapien ist ein
tieferes Versta¨ndnis des Zusammenhangs von Epigenom und zellula¨rer Funktion wichtig.
Im Rahmen dieser Dissertation war es mein Ziel, differenzierende Stammzellkulturen auf ihre
Genexpression, ihre Chromatinregulation und ihr Differenzierungspotiential hin zu analysie-
ren.
Um Histonmodifikationen, die einen mo¨glichen Mechanismus epigenetischer Regulation dar-
stellen, global untersuchen zu ko¨nnen, sind zuna¨chst, durchflusszytometrische Protokolle eta-
bliert worden, die die Analyse einzelner Zellen ermo¨glichen sollten. Mit dieser Methode konn-
ten reduzierte Levels von Histonazetylierung in differenzierten ES Zellen gezeigt werden. Im
Gegensatz dazu beobachtete ich vergleichbare Levels von Histonazetylierung in unreifen und
reifen Knochenmarkzellen.
Zusa¨tzlich untersuchte ich die Wirkung des Histondeazetylase-Inhibitors (HDI) Trichostatin
A (TSA) auf Knochenmarkzellkulturen, in denen auch HSZs enhalten sind. Nach Behandlung
mit TSA erho¨hte sich der Anteil von Zellen mit in vitro und in vivo ha¨matopoetischer Akti-
vita¨t, wa¨hrend vor allem differenzierte Zellen in Apoptose gingen.
Außerdem wurde der Verlust der Pluripotenz in differenzierenden ES Zellkulturen unter-
sucht. Marker-basierte Analysen und funktionelle Tests wurden mit ES Zellen durchgefu¨hrt,
die kurzfristig in vitro differenziert wurden. Es stellte sich heraus, dass nach funktionellen
Gesichtspunkten die Pluripotenz bereits nach 2 Tagen Differenzierung deutlich reduziert war,
beurteilt anhand der Fa¨higkeit Kolonien zu bilden, embryoide Ko¨rperchen (EK) zu formieren
und zu kontrahierenden Herzmuskelzelltypen zu differenzieren. Im Gegensatz dazu verringerte
sich die Expression von Pluripotenzmarkern erst zu spa¨teren Zeitpunkten. Ich habe weiterhin
beobachten ko¨nnen, dass die Wahl des Differenzierungssystems (Aggregations-EK, klonale
EKs oder als adha¨rente Einzelzellschicht) einen Einfluss auf den Fortschritt und die Homo-
genita¨t der Differenzierung hatte. Um das Ende der Pluripotenz genauer zu untersuchen,
wurden differenzierte ES Zellen zuru¨ck in ES Zellkulturbedingungen gebracht. Die Ergebnisse
deuten an, dass 3 Tage differenzierte ES Zellen einen Punkt u¨berschritten haben, an dem
eine Ru¨ckkehr zur Pluripotenz allein durch Kulturbedingungen noch mo¨glich ist. Durch die
Behandlung mit HDIs starben selektiv differenzierte ES Zellen.
Des Weiteren war es Ziel dieser Arbeit, den Einfluss von EED - einer essentiellen Unterein-
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heit des Histon-methylierenden Polycomb repressive complex 2 (PRC2) - auf das Chromatin
und die Funktion von ES Zellen hin zu analysieren. ES Zellen ohne EED wiesen neben dem
bereits bekannten Verlust der Trimethylierung von Histon 3 an Lysin 27 (H3K27me3), global
reduzierte H3K9me3 Levels sowie erho¨hte Histonazetylierung auf. Trotz typischer ES Zell-
Morphologie und normaler Expression von Pluripotenzgenen, besaßen EED knockout (KO)
ES Zellen eine vera¨nderte Organisation der Heterochromatinstruktur im Zellkern, eine ver-
langsamte Chromatinmobilita¨t und Probleme bei der Differenzierung.
Zusammenfassend gewa¨hren meine Daten Einblick in die epigenetische Regulation von Stamm-
zellen. Im Besonderen konnte ich zeigen, dass die Behandlung mit HDIs fu¨r differenzierende
Knochenmarkzellen und differenzierende ES Zellen nachteilig war und zu deren selektivem
Zelltod fu¨hrte. Die hier durchgefu¨hrten Analysen ergaben, dass ES Zellen nach 3 Tagen Dif-
ferenzierung das Ende der Pluripotenz erreicht hatten. Schließlich zeigten die Versuche mit
EED KO ES Zellen, dass sie sich zwar selbst erneuerten und morphologisch identisch mit
wildtypischen ES Zellen waren, jedoch Defekte bei der Differenzierung besaßen. Dies deu-
tet darauf hin, dass EED nicht nur fu¨r undifferenzierte ES Zellen wichtig ist, sondern auch
wa¨hrend der Differenzierung von Bedeutung ist.
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3 Abbreviations
7AAD 7 amino actinomycin D
ac acetylation
AFP alpha fetoprotein
AP alkaline phosphatase
approx. approximately
ATRA all trans retinoic acid
BM bone marrow
Bry brachyury
BSA bovine serum albumine
ChIP chromatin immunoprecipitation
d day(s)
DAPI 4’,6-diamidino-2-phenylindole
DMEM Dulbecco’s modified eagle medium
DMSO dimethylsulfoxide
Dnmt DNA methyltransferase
dNTP deoxynucleotide triphosphate
dps day(s) post sort
EB embryoid body
ECL enhanced chemiluminescence
EED embryonic ectoderm development
e.g. exempli gratia, for example
EGF epidermal growth factor
eGFP enhanced green fluorescent protein
EpiSC epiblast stem cell
ES embryonic stem
et al. et alii, and others
EZH2 enhancer of zeste 2
FACS fluorescence activated cell sorting
FCS fetal calf serum
FGF fibroblast growth factor
FisH fluorescence in situ hybridisation
GSK3 glycogen synthase kinase 3
h hour(s)
H histone
HAT histone acetyltransferase
HD hanging drop
HDAC histone deacetylase
HMT histone methyltransferase
HPC hematopoietic progenitor cell
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3 Abbreviations
HPSC hematopoietic progenitor and stem cell
HRP horseradish peroxidase
HSC hematopoietic stem cell
ICM inner cell mass (of blastocyst)
i.e. id est, that is
IL interleukine
IMDM Iscove’s modified Dulbecco’s medium
K lysine
KDM histone lysine demethylase
KO knockout
LIF leukemia inhibitory factor
Lin lineage
LKS Lin−, c-Kit+, Sca1+
LT long-term
MACS magnetic cell separation
MBD methyl-CpG-binding domain protein
MC methylcellulose
me methylation
MEF mouse embryonic fibroblast
MEK mitogen-activated protein kinase/ERK kinase
MTG monothioglycerol
NSC neural stem cell
PBS phosphate buffered saline
PRC2 Polycomb repressive complex 2
PWM Pokeweed mitogen
RT room temperature
s second(s)
Sca1 stem cell antigen 1
SCF stem cell factor
SDS sodium dodecylsulfate
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis
SSEA1 stage specific embryonic antigen 1
ST short-term
SUZ12 suppressor of zeste 12
TC tissue culture
trxG Trithorax group
TSA trichostatin A
TSS transcriptional start site
VPA valproic acid
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4 Introduction
4.1 Stem cells
4.1.1 Characteristics of stem cells
The evolution of multicellular organisms brought about the establishment of hierarchic cellular
systems with tightly regulated cell proliferation and differentiation processes [1]. Stem cells
constitute the cellular origin of various adult tissues and organisms. Stem cells are functionally
defined by their capability to self renew and their potential to differentiate into multiple cell
lineages [2, 3]. The fertilized egg of vertebrates, i.e. a zygote, is the stem cell with the highest
developmental potential. This cell can self renew by giving rise to blastomeres with the same
potential. The zygote itself and blastomeres are considered totipotent stem cell types, because
they can differentiate into every cell type of an entire multicellular individual [4]. In contrast,
pluripotent stem cells can generate all embryonic cell types but they fail to differentiate into
extraembryonic tissue like trophectoderm. Pluripotent stem cells are generated in the inner
cell mass (ICM) of blastocyst stage embryos. Placed in in vitro cultures ICM cells give rise
to pluripotent embryonic stem (ES) cell lines that can be stably propagated in culture [5, 6].
Upon injection into blastocysts ES cells take part in normal multicellular development of the
embryo. ES cell lines were so far generated from mouse, human and other species [7, 5, 6, 8].
Besides in the embryo, stem cells have crucial functions also in the adult body. Here they are
the origin of tissue regeneration and cellular homeostasis, as they generate offspring that can
replace aged and injured cells [9, 10, 11, 12, 13]. Adult stem cells are multi- or unipotent,
i.e. they generate differentiated cells of their stem cell system. They reside in specialized
niches within the organ or tissue that they can reconstitute [14, 15]. For instance, adult
neurogenesis is achieved by a small population of neural stem cells (NSCs) which are located
in the subventricular zone of the lateral ventricle [16]. Similarly, hematopoietic stem cells
(HSCs) reside in trabecular structures of the bone marrow (BM) [17]. While ES cells exhibit
high proliferation rates, adult stem cells often persist in a quiescent state and therefore rarely
divide [18].
Stem cells are of particular interest for basic and applied research. For example, stem cell
model systems can serve to address fundamental epigenetic questions, as upon differentiation
of stem cells not the genetic information but rather the chromatin is modified [19]. ES cells
are utilized in studies that aim to model in vitro embryogenesis and test for embryotoxic
substances [20, 21]. Finally, stem cells are in the focus of therapeutic approaches to cure or
replace aged and injured tissues or organs. In the future, pluripotent ES cells with their broad
differentiation potential could be used for guided differentiation towards specific directions as
in the context of tissue replacement.
4.1.2 Embryonic stem cells: pluripotency, differentiation and reprogramming
ES cells are in vitro derivatives of ICM cells of blastocyst-stage embryos [6]. Like ICM cells
ES cells are pluripotent and can differentiate into all ecto-, endo- and mesoderm cell lineages
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including germ cells. Murine ES cells can be maintained in vitro in an undifferentiated, self
renewing state [6]. Typically ES cells grow as packed colonies on a layer of mouse embry-
onic fibroblasts (MEFs) in media supplemented with leukemia inhibitory factor (LIF). LIF
binds to gp130 / LIF receptor and activates STAT3 via the JAK/STAT signaling pathway
[22]. Subsequently, expression of factors like Nanog, Klf4 and c-myc is induced by STAT3,
thereby promoting the undifferentiated state [23, 24, 25]. ES cells exhibit a highly regulated
molecular network of transcription factors that enables the maintenance of the groundstate
of pluripotency [26]. Oct4, Sox2 and Nanog represent core pluripotency transcription fac-
tors which act in concert on downstream targets and on an autoregulatory base [27]. The
homeodomain transcription factor Oct4 belongs to the POU family of transcription factors.
Oct4 is expressed in totipotent cells and subsequently in the ICM of blastocysts but not in
the trophectoderm, where it is repressed by Cdx2 [28, 29]. Apart from ES cells, epiblast
stem cells and germ cells also express Oct4. In ES cells Oct4 protein levels are kept within
a defined range, as too low levels cause the loss of pluripotency and stimulate differentiation
into trophectoderm [30]. On the other hand, high levels induce ES cell differentiation into
endo- and mesodermal directions [30]. Oct4 and Sox2 proteins form heterodimers which can
bind their own promoters in order to sustain Oct4 and Sox2 gene expression.
In vivo the epiblast of a preimplantation blastocyst develops into primed epiblast cells upon
nidation. While ES cells are established from preimplantation blastocysts, epiblast stem cells
(EpiSCs) can be derived from primed epiblast cells and propagated in vitro [31] (Scheme 4.1).
Recently, it became obvious that murine ES cell cultures are not homogenous but rather het-
erogenous. For example gene expression analyses of single ES cells revealed that expression
levels of pluripotency factors like Rex1, Nanog, SSEA1 or Stella vary to a great extent and
are fluctuating [32, 33, 34, 35, 36]. It is hypothesized that cells with lower levels of these fac-
tors are similar to EpiSCs (i.e. they are epiblast-like cells), but that this cell population can
occasionally revert to groundstate of pluripotency under standard ES cell conditions. It was
further reported that a serum-free culture medium supplemented with inhibitors of glyco-
gen synthase kinase 3 (GSK3) and mitogen-activated protein kinase/ERK kinase (MEK)
allows the maintenance of ES cells as a homogenous population without fluctuation towards
epiblast-like cells [37]. GSK3 and MEK inhibitors block signal pathways that are active in
lineage committing ES cells. Under these groundstate conditions ES cells are not dependent
on external stimuli like LIF and do not differentiate. Recent studies also demonstrate the
conversion of EpiSCs to ES cells by appropriate culture conditions in the presence of LIF or
small molecules [38, 39].
The question of whether cells are pluripotent can be assessed on different levels of stringency.
While the expression of pluripotency markers gives first hints about a cell’s developmental
potential, functional parameters are more reliable. A more stringent test is the assessment of
ES cell growth and multilineage differentiation potential in vitro. Pluripotent ES cells form
typical colonies when self renewing and generate embryoid bodies (EBs) upon withdrawal of
LIF or GSK3/MEK inhibitors. Upon differentiation induction ES cells spontaneously and
undirectedly start to express molecular programs of differentiated cells. In vivo upon sub-
cutaneous injection, ES cells form teratomas that are constituted of differentiated cells of
the three germ layers [40]. The formation of germline-competent chimeras after injection of
ES cells into blastocysts represents the most stringent test for pluripotency [41]. By using
tetraploid blastocysts, which can only form extraembryonic tissue but fail to develop into the
embryoblast, injected truly pluripotent ES cells give rise to the entire embryo [42].
The remarkable in vitro differentiation potential of ES cells makes them an interesting cell
14
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Scheme 4.1: Embryonic and epiblast stem cells.
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of early blastocyst stage embryos.
Epiblast stem cells (EpiSCs) are established for in vitro culture from postimplantation blastocysts. ES cells
like EpiSCs express similar levels of the pluripotency marker Oct4 and can differentiate to cells of all 3 germ
layers. They differ in expression levels of several genes like Rex1, Nanog or Stella. Female EpiSCs exhibit
an inactivated X chromosome with methylated DNA. Cultures of ES cells where found to be heterogeneous
because cells undergo interconvertible fluctuations between cellular identities similar to ES cells and others
similar to EpiSCs (epiblast-like cells). (modified from Hayashi et al. [36])
type for tissue replacement approaches. With the establishment of human ES cells approx. 10
years ago ES cell-based cell replacement strategies came within closer reach [8]. In October
2010 Geron Corporation initiated a first clinical trial of human ES cell-based therapy [43]. ES
cells were so far successfully differentiated towards many clinically relevant cell types includ-
ing cardiomyocytes, dopaminergic neurons and pancreatic beta-cells [44, 45, 46, 45]. However,
potential remnants of undifferentiated ES cells within differentiated cell populations display
a considerable risk of teratoma-tumor formation upon transplantation [47, 45]. Therefore, it
is essential to define safety criteria and standardized differentiation protocols before clinical
application.
Usually, upon in vitro differentiation murine ES cells form EBs that represent aggregates
of differentiating ES cells [48, 49]. For that a defined number of differentiating ES cells is
clustered to one EB by gravity in hanging drops (HDs) of differentiation medium. For dif-
ferentiation of ES cells towards hematopoietic cell types it was reported that the formation
of EBs in semisolid medium yielded higher hematopoietic differentiation outcomes than the
formation of EBs by ES cell aggregation [50]. For this purpose, individual EBs emerge from
single differentiating ES cells in a methylcellulose (MC)-based medium that prevents random
clustering. Alternatively, ES cells can also be differentiated as adherently growing monolayer
(ML) cells in the absence of LIF [51]. To a certain extent the ongoing differentiation within
EBs mimics embryonic development, but different cell lineages stochastically appear during
in vitro ES cell differentiation. To further direct differentiation towards defined cell types, cell
type-specific selection methods and/or cell type-specific growth conditions must be applied
15
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[44].
The studies on pluripotency not only involve differentiation strategies, but also include the
analyses of mechanisms that lead to reprogramming of differentiated cells towards cell types
with higher developmental potential. So far different methods of reprogramming of somatic to-
wards pluripotent cells were successfully developed [52]: somatic cell nuclei are reprogrammed
upon transfer into enucleated oocytes (somatic cell nuclear transfer [SCNT]), somatic cells
are reprogrammed upon fusion to ES cells or by ectopic expression of Oct4, Sox2 and Klf4
(induced pluripotent stem [iPS] cells). In all 3 approaches it is most probably the activity
of pluripotency factors (either in the oocyte-plasm, in the ES cell-plasm or directly by the
expression of pluripotency factors) which induces reprogramming. Especially the identifica-
tion of the ’magic cocktail’ using Oct4, Sox2, Klf4 (and c-myc) transgenes by Takahashi and
Yamanaka set a milestone in rational pluripotency and reprogramming research [53]. The
directed reprogramming approach with defined factors allows deeper molecular analyses help-
ing to better understand regulation of pluripotency. Until now iPS cells could successfully
be generated from many species including human [54]. They are hardly distinguishable from
normal ES cells, even though recent reports raise the issue of an epigenetic memory and in-
complete reprogramming dependent on the somatic tissue of origin [55, 56].
4.1.3 Hematopoietic stem cells
Hematopoietic stem cells (HSCs) are multipotent adult stem cell types that can differentiate
into all hemato-/lymphoid blood cell lineages [57, 58]. In small numbers they reside in the
bone marrow (BM) where they undergo either symmetric or asymmetric cell division to give
rise to either two daughter HSCs, two hematopoietic progenitor cells (HPCs) or to one HSC
and one HPC [59]. In the BM niches HSCs underly extrinsic and intrinsic signals that regulate
their self renewal, differentiation and migration [60]. The hematopoietic system is character-
ized by a hierarchic structure [61] (Scheme 4.2). HSCs at the top of the hierarchy combine
a high self renewal potential with a low cell division rate. They are referred to as long-term
repopulating (LT) HSCs. Short-term (ST) HSCs exhibit equal unrestricted differentiation ca-
pacity, but their pool is depleted earlier as they show limited self renewal potential. ST-HSCs
can differentiate into multipotent progenitors (MPPs) which likewise have the capability to
form all types of blood cells but their self renewal potential is further restricted. MPPs dis-
play a rapidly dividing cell population and their derivatives are either common lymphoid or
common myeloid progenitors (CLPs, CMPs) [61]. Hematopoietic progenitor and stem cells
(HPSCs) can be isolated from the BM or after mobilization from the peripheral blood. Their
purification is based on the presence or absence of specific surface marker proteins that are
characteristic for LT-/ST-HSCs. For instance, murine LT-HSCs are defined by the following
marker status: CD34−, Sca1+, Thy1.1+, c-Kit+, Lin−, Flk2− [62]. Sca1 represents stem
cell antigen 1, c-Kit is the receptor for the stem cell factor (SCF) and lineage (Lin) markers
are proteins expressed on the surface of committed cells (including lymphocytes [CD4, CD8,
B220], macrophages [Mac1], granulocytes [Gr1] and erythrocytes [Ter119]). BM cells with
the marker signature Lin−, c-Kit+ and Sca1+ (short: LKS cells) comprise LT-HSCs, ST-
HSCs but also MPPs [62]. On the basis of their individual marker expression profiles HSCs
and HPSCs can be purified by fluorescence activated cell sorting (FACS). For experimental
transplantation in the mouse model but also in human settings HPSCs can be given intra-
venously, whereupon the cells re-invade into BM niches of the recipient by a process named
16
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homing [63, 64]. Today, HSCs are used in multiple clinical settings as therapeutics [65]. The
hematopoietic system constitutes the best and longest studied stem cell system.
In contrast to various embryonic and adult stem cell types, efficient ex vivo expansion of HSCs
remains challenging, despite the enormous efforts that were undertaken over the past decades
[66]. Previously it was reported that ectopic expression of the homeotic transcription factor
HoxB4 leads to expansion of HSCs ex vivo [67]. Later it could be shown that purified HSCs of
human umbilical cord blood origin can be expanded by treatment with the nucleoside analog
5-aza-2’-deoxycytidine (5azaD) and trichostatin A (TSA), an inhibitor of histone deacetylases
(HDAC), respectively [68, 69]. During the last years the design of artificial HSC niches using
biopolymer matrices also led to a limited expansion of HSCs [70, 71]. Very recently, a small
molecule screen by Boitano et al. identified an aryl hydrocarbon receptor antagonist, Stem-
Regenin1, that supports robust ex vivo HSC expansion [72].
Scheme 4.2: Hematopoietic stem cell systemt.
Multipotent hematopoietic stem cells (HSCs) have the potential to self renew and to differentiate into all
hemato-/ lymphoid cell lineages. Self renewal capacity is highest in long-term (LT) HSCs which can long-
term and multilineage reconstitute irradiated recipients. Short-term (ST) HSCs have a limited self renewal
potential, while multipotent progenitors (MPP) can not self renew but have full differentiation capability.
Common lymphoid and myeloid progenitors (CLP, CMP) represent first committed cell types and give rise to all
blood lineages including erythrocytes, lymphocytes, granulocytes, megakaryo-/thrombocytes and macrophages.
(modified from Rosenbauer et al. [61])
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4.2 Epigenetics
4.2.1 Epigenetic mechanisms
Cells store genetic information in the base sequence of their genomic DNA. Upon mitosis this
information is propagated through the equal distribution of duplicated DNA to the 2 daugh-
ter cells. With the emergence of multicellular organisms and the specialization of distinct
tissues, cells with identical genomes but different cellular functions developed. Though the
information of approx. 20,000 genes is present in all cells of the body, individual gene activity
strongly depends on the respective cell type. Thus, cells develop cell type-specific chromatin
that enables the activation of some genes and the inhibition of others. Epigenetics is the
study of inherited changes in phenotype or gene expression caused by mechanisms other than
changes in the underlying DNA sequence. These changes remain through cell divisions [73].
Stem cells represent a powerful tool for the investigation of epigenetic mechanisms. During
self renewal epigenetic information must be preserved and propagated whereas upon differ-
entiation epigenetic properties change [74]. Deeper insights into epigenetics are needed to
better understand the molecular regulation of stem cells.
Mechanisms that result in different gene activity comprise chemical modification of DNA and
histones, functionally versatile non-coding RNAs, transcription factors and chromatin com-
paction. Also transcription factors that activate cell type-specific gene expression programs
function on an epigenetic level [75]. Enzymes with the activity to methylate DNA at CpG sites
are called DNA methyltransferases (Dnmt) [76]. The methylation of DNA is generally accom-
panied by the inactivation of genes. The silencing of genes via DNA methylation is believed to
be stable and persistent, however, in recent years different DNA demethylating mechanisms
were uncovered. These include the direct removal of methyl residues via demethylating en-
zymes or alternative pathways that utilize DNA repair enzymes [77]. Methylated DNA serves
as a binding site for methyl-CpG-binding domain proteins (MBD) that can recruit other chro-
matin modifying proteins and complexes. Generally these complexes further mediate gene
silencing.
Histones are proteins that function in the ordered package of DNA into structural units [78].
Two molecules of histone H3 and H4 form together with H2A and H2B the octamer spool
around which 146 bp of DNA are wound. This structure is named nucleosome. N-terminal hi-
stone tails of core histones are reversibly and covalently modified by acetylation, methylation,
ubiquitination, phosphorylation, SUMOylation, citrullination or ADP-ribosylation. These
modifications are either directly involved in the activation of gene expression (e.g. histone
acetylation) or they function as recognition sites for protein complexes. By recruitment of
defined multifactorial protein complexes the expression or silencing of corresponding genes
is modulated. The genome-wide pattern of histone modifications in a particular cell type
is referred to as histone code, which is hypothesized to contain epigenetic information like
the base pair code of DNA contains genetic information [79]. However, the histone code is
not universal as different histone modifications can be recognized by more than one protein
complex and hence, the subsequent effects can be of different nature [80]. In recent decades
mechanisms of histone acetylation and methylation were extensively studied. While the exis-
tence of enzymes that add acetyl-groups (histone acetyl transferases, HAT) or remove them
(histone deacetylases, HDAC) is well established, the discovery of histone lysine demethylases
(KDM) besides well-known histone methyltransferases (HMT) was a recent event [81, 82, 83].
Lysine residues of histones H3 and H4 can be mono-, di- or trimethylated. The quantity
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and position of lysine methylation plays an important role in whether the modifications are
associated with transcriptional activation or repression. For example, the trimethylation of
histone H3 at lysine (K) residue 4 (H3K4me3) is generally present at transcriptionally active
loci whereas H3K27me3 is associated with repressed genes.
Further epigenetic mechanisms comprise non-coding RNAs [84]. They can function as mi-
croRNAs to either degrade transcripts or inhibit translation of target mRNA. Also it was
reported that non-coding RNA molecules can bind to genomic DNA and thereby recruit pro-
tein complexes that recognize non-coding RNA like an adaptor.
Generally chromatin within mammalian nuclei is composed of transcriptionally active euchro-
matin and transcriptionally inactive heterochromatin [85]. In heterochromatin nucleosomes
are densely assembled with a high degree of compaction, thus leading to inaccessible DNA and
silenced genes. In contrast, euchromatin is characterized by rather loosely packed nucleosomes
that are accessible to the transcriptional machinery. DNA methylation and hypoacetylated
histones are enriched in heterochromatin, whereas unmethylated DNA and hyperacetylated
histones are present in euchromatin. The movement of nucleosomes along DNA which re-
sults in compaction or decondensation is achieved by ATP-dependent nucleosome remodeling
complexes. These complexes push nucleosomes like beads on a string and thereby regulate
eu-/heterochromatin and gene activity epigenetically [86].
4.2.2 Histone acetylation and HDAC inhibition
Histone acetylation represents one mechanism of epigenetic regulation by which gene activ-
ity can be modulated. Two principle mechanisms are operating [87]: firstly, the acetylation
of histone lysine residues weakens the electrostatic affinity of the negatively charged DNA
and the positively charged histones. Therefore, chromatin structure becomes loosened and
DNA is more accessible for transcription factors and RNA polymerases. Secondly, acetylated
lysine residues serve as recognition sites for bromodomain protein complexes. In this case
it is decisive which position the acetylated lysine residue has and which type of histone is
involved. The sites of acetylation include at least four highly conserved lysine residues of
histone H4 (K5, K8, K12 and K16), five of histone H3 (K9, K14, K18, K23 and K27), as well
as less conserved sites in histones H2A and H2B [88]. The catalytic reaction of acetylation
is performed by HAT enzymes that transfer an acetyl group from acetyl CoA resulting in
ε-N-acetyl lysine. The deacetylation of histones is accomplished by HDAC enzymes. So far,
11 members of the HDAC family have been identified. They are subdivided into 4 classes:
class I comprises HDAC 1, 2, 3, 8, class II contains HDAC 4, 5, 6, 7, 9, 10, class III includes
the sirtuins and class IV is represented by HDAC 11 [89]. Acetylation of histones is balanced
in an equilibrium by the 2 opposing enzymatic activities. Recent data suggest that HDACs
and HATs are simultaneously present at regulatory sites of active genes allowing fast and
flexible modulation of gene expression [90].
The activity of HDACs can be reduced by treatment with HDAC inhibitors, thereby indi-
rectly inducing histone hyperacetylation [91]. Classical HDAC inhibitors affect class I and
II HDACs by interacting with their catalytic domains. One of these inhibitors is the Strep-
tomyces metabolite TSA, a hydroxamic acid [92]. Also aliphatic acid compounds such as
valproic acid (VPA) inhibit HDACs. Beneficial effects in clinical application of HDAC in-
hibitors were determined rather empirically. VPA is in use as anti-epileptic drug since long
time and it is currently under investigation for several cancer treatment approaches including
leukemia [93, 94]. TSA is under clinical test as anti-inflammatory agent [95]. Whether the
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therapeutic efficacy of these compounds is based on the resulting histone hyperacetylation
remains however questionable. As different HDAC inhibitors exert distinct disease-specific
effects, it is possible that drug-specific (side) effects other than HDAC inhibition are respon-
sible for the entire spectrum of HDAC effects. Further, HDACs were also shown to affect
deacetylation of non-histone proteins such as tubulin [96, 97]. Thus, HDAC inhibition po-
tentially affects multiple biological processes besides chromatin regulation. To date reports
on TSA describe various effects on different cell types: exposure of leukemic U937 cells to
TSA results in growth inhibition and induction of apoptosis [98]; TSA treatment of fetal
brain-derived NSCs increases neuronal and decreases astrocyte differentiation [99]; addition
of TSA to MEFs transduced with reprogramming genes enhances iPS cell-generation [100];
together with the Dnmt inhibitor 5azaD TSA leads to net expansion of CD34+ human cord
blood cells [69, 68].
4.2.3 Epigenetics of pluripotent cells
The remarkable differentiation potential of pluripotent cells is mirrored in their chromatin
organization. Especially hyperdynamic chromatin plasticity and bivalently regulated genes
in ES cells represent exceptional and pluripotency-associated features.
Hyperdynamic chromatin
Several discoveries within the last decade shed light on a highly flexible and permissive state
of chromatin in ES cells [101]. Flexibility of gene expression is a hallmark feature of ES cells
which can only be achieved if respective genes are not permanently silenced. An open and
unrestricted chromatin architecture is therefore a fundamental prerequisite for this state.
Electron microscopy of ES cell nuclei revealed that their chromatin is homogeneous, decon-
densed and rich in euchromatin. In contrast, differentiated nuclei exhibit frequent, distinct
heterochromatin domains [102, 103]. While heterochromatin domains in ES cells are rather
diffuse, upon differentiation to NSCs they become more defined with distinct boundaries [104].
Euchromatin is generally associated with a transcriptional activity of genes, and indeed global
transcription levels are elevated in ES cells as compared to differentiated cells [102]. The dy-
namics, i.e. the molecular exchange rates, of chromatin proteins are higher in ES cells than
in differentiated progeny [104, 105]. By fluorescence recovery after photobleaching (FRAP)
analyses of GFP-tagged proteins like heterochromatin protein 1 (HP1), histone H1 or core
histones, fast and highly mobile chromatin fractions were discovered in pluripotent cells [104].
Global levels of histone modifications which are accompanied by gene activity are higher in
ES cells than in differentiated cells. Histone modifications such as H3K9ac but also H3K14ac,
H3K4me3 and H3K36me3 are prevalent in undifferentiated ES cells [104, 106, 102, 107, 108,
109]. In contrast, levels of repressive histone modifications, like H3K9 methylation or HP1,
become globally elevated upon differentiation [104, 102, 106, 109, 110, 111].
High chromatin dynamics and large euchromatin proportions are most probably the result
of ATP-dependent chromatin remodeling complexes [112]. These enzymes are responsible
for the generation of an accessible DNA configuration and for opening chromatin structures.
These enzymes are highly abundant in undifferentiated ES cells and comprise BAF250B, Bptf,
BAF155 and Chd1 [102, 113, 114, 115, 116, 117, 118].
Thus, the chromatin of pluripotent ES cells is characterized by an overall and high accessibil-
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ity and transcriptional hyperactivity, thereby preventing permanent silencing of genes which
are associated with cell lineage commitment. However, to avoid uncontrolled expression of
genes that are not required at the groundstate of pluripotency, cells must interpose flexible
repressive regulatory mechanisms. One example for this are bivalently controlled chromatin
domains.
Bivalent chromatin domains
Bivalent chromatin domains are characterized by the simultaneous presence of repressive
H3K27me3 and activating H3K4me3 marks at regulatory sites of genes which are involved
in lineage commitment, differentiation and tissue development [119, 120] (Scheme 4.3). As
the repressive H3K27me3 modification appears dominant over H3K4me3, bivalent genes are
expressed at only low levels in pluripotent ES cells. However, upon differentiation respective
genes can either be immediately activated by removing the H3K27me3 modification via spe-
cific KDMs or expression can stably be repressed by demethylation of H3K4. This mechanism,
which leads to a flexible epigenetic control of gene expression programs upon external or inter-
nal stimuli, is not only a feature of pluripotent but also of multipotent HPSCs [121, 122, 123].
The activating methylation of H3K4 is catalyzed by Trithorax group (trxG) proteins that
comprise 8 different enzymes, e.g. MLL1, MLL2, SET1A and ASH1 [83]. At least 6 different
proteins were identified as H3K4-specific KDMs (like LSD1 or JARID1A). Methylation of
H3K27 is accomplished by EZH2 or its homolog EZH1 which are the core subunits of the
Polycomb repressive complex 2 (PRC2) [125]. Two demethylating enzymes, KDM6A (UTX)
and KDM6B (JMJD3), were described for lysine 27 [83].
For the efficient repression of bivalent genes upon lineage commitment different mechanisms
are discussed. While in ICM and in ES cells genes are silenced by H3K27me3 and subsequent
recruitment of PRC1 and RING1B-mediated H2A ubiquitination, in extraembryonic lineages
genes are repressed via recruitment of Suv39H1 to H3K27me3, leading to subsequent H3K9
and DNA methylation [126, 127].
Polycomb repressive complex 2
The PRC2 consists of 3 core subunits: EZH1/2 (enhancer of zeste), EED (embyonic ecto-
derm development) and SUZ12 (suppressor of zeste) [128] (Scheme 4.4). The homologs EZH1
and EZH2 represent the executing H3K27 HMT enzymes, the two can substitute for each
other [125]. EED exists in 4 different isoforms that are the result of different translational
start sites in the EED mRNA [129]. Stability of the PRC2 is dependent on the presence
of all 3 subunits. Knockout (KO) ES cell lines of EZH2, SUZ12 and EED were successfully
generated [125, 130, 131]. Interestingly, only EED KO or EZH2 KO combined with EZH1
RNAi-mediated knockdown (KD) leads to loss of H3K27 mono-, di- and trimethylation. EZH2
KO and SUZ12 KO reduce di- and trimethylation while H3K27me1 remains unaffected.
Neither EZH2 nor EED or SUZ12 can directly bind to target DNA motifs. Currently different
models for the interaction of PRC2 with its target regions are discussed. It was described
that EED binds with its WD40 domains to unmodified histone H3 but also specifically to
H3K27me3 and H3K9me3 modified histones [132, 133, 134]. The interaction with H3K27me3
was shown to enhance the enzymatic activity of EZH2 allosterically, thus promoting H3K27
methylation. Thereby the repressive modification is transmitted to new histones during DNA
replication and epigenetic heritability is achieved. Recently the interplay between non-coding
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Scheme 4.3: Regulation of bivalent chromatin domains in ES cells.
Bivalently regulated chromatin domains simultaneously carry histone marks associated with gene activation
(H3K4me3) and repression (H3K27me3). Bivalently regulated genes are repressed or expressed at only low
levels in ES cells. They are related to development and differentiation. Bivalent genes are poised for future
expression by the presence of activiating H3K4me3 marks. While Trithorax group proteins (trxG)) catalyze
H3K4 methylation and Polycomb repressive complex 2 (PRC2) perform H3K27 methylation, specific lysine
demethlyases (KDMs) remove respective methylation marks. Therefore, bivalent genes become stably repressed
by H3K4 demethylation via LSD1 or JARID1 and expression of bivalent genes is mediated by the removal of
H3K27 trimethylation by UTX or JMJD3. (modified from Pietersen et al. [124])
RNAs and PRC2 was discovered as a mechanism for gene targeting [135, 136]. It was shown
that non-coding RNAs polymerized from PRC2-repressed genes serve as connector between
genomic sites and SUZ12.
Besides the core subunits of PRC2 further proteins were identified to be assembled into the
multifactorial PRC2 complex, e.g. Dnmt, Suv39h1, HDACs and Jarid2 [137, 138, 139, 140,
141, 142]. Notably, the presence of Jarid2 in the PRC2 was suggested to guide the complex
to its target sites, as Jarid2 contains a DNA binding domain. Further, Jarid2 most probably
interacts via SUZ12 and Jarid2 was found to be co-localized with PRC2 and its respective
histone modification in ES cells [143, 144, 145, 146].
The PRC2 complex plays an important role in the establishment and maintenance of the
distinct ES cell chromatin, as the H3K27me3 histone mark has essential gene regulatory
functions, particularly the repression of development-associated genes. Thus, it is not sur-
prising that in ES cells the expression of EED is directly regulated by Oct4. As a direct
consequence EED expression is decreased during differentiation [147]. Furthermore, EED is
necessary for successful reprogramming of somatic B lymphocytes upon fusion with ES cells
[148]. ES cells lacking EED are unable to perform fusion-based reprogramming of B lympho-
cytes even if simultaneously merged to another wild type ES cell, indicating an inhibitory
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effect of EEDnegative nucleo- or cytoplasm on reprogramming.
In vivo EED KO embryos die during mid gestation (E10.5) [149]. Similarly chimeric embryos
derived from the injection of EED KO ES cells into blastocysts die at comparable develop-
mental stages [150]. Despite elevated transcription levels of PRC2 target genes in EED KO
ES cells, the expression of pluripotency-associated genes remains unperturbed, and differen-
tiation - at least to a certain extent, including cell types of the 3 germ layers - is possible.
However, an additional deletion of the PRC1 member RING1B in EED KO ES cells results
in completely abrogated differentiation [151]. PRC1 and PRC2 act redundantly to repress
development-associated genes in ES cells. Thus, the derepression of all of these genes blocks
ES cell differentiation.
The PRC2 complex and its members were also shown to exhibit non-chromatin, cytosolic
functions. EZH2 is involved in actin polymerization and EED is linked to TNF receptor
signaling [152, 153]. In addition, PRC2, particularly EZH2, is linked to several cancers and
supposed to be responsible for epimutations [154].
Thus, a better understanding of chromatin regulation by PRC2 will shed light on elementary
developmental processes but also on disease-related mechanisms.
Scheme 4.4: Polycomb repressive complex 2.
The Polycomb repressive complex 2 (PRC2) is composed of the core subunits SUZ12, EED and EZH2. Ad-
ditional proteins found to be assembled with PRC2 are histone deacetylases (HDACs), the H3K9 histone
methyltransferase (HMT) Suv39h1, DNA methyltransferases (Dnmts) and Jarid2. EED can directly bind to
H3K9me3 and H3K27me3. Binding to H3K27me3 leads to allosterical activation of the H3K27 HMT activ-
ity of EZH2. Genomic targeting of PRC2 is assumed to be mediated via either direct DNA interaction of
Jarid2 which binds to SUZ12 or via non-coding RNAs that recruit SUZ12 to target loci. Histone octamers are
displayed as grey spheres, only one copy of histone H3 and its N-terminus is exemplarily denoted per octamer.
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4.3 Scientific aims of this thesis
Our current knowledge about the molecular regulation of adult and embryonic stem cells
points to important roles of epigenetic mechanisms. In the scope of this thesis I aimed to
analyze cultures of differentiating hematopoietic and embryonic stem cells with respect to
gene expression, chromatin structure and stem cell function. The first part of the work
focuses on the analysis of HDAC inhibitor effects on cell death, differentiation and HPSC
activity in ex vivo murine BM cell cultures. The second part comprises studies on the early
in vitro differentiation progression of mouse ES cells. It includes analyses on the influence
of differentiation protocols on the loss of pluripotency. Further, I address the question of
whether short-term differentiated ES cells can revert to pluripotency by re-addition of LIF
in the presence or absence of HDAC inhibitor treatment. The final part of this thesis deals
with the functional and chromatin-associated exploration of ES cells that lack the PRC2
core member EED. A detailed understanding of stem cell regulation on the molecular level is
essential for deeper insights into normal and diseased stem cells functions.
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5.1 Establishing chromatin flow cytometric protocols
Analyses of defined cells, such as rare stem cells, within heterogeneous cell populations con-
cerning chromatin modifications is technically challenging. As flow cytometry allows the
analysis of subpopulations, because it measures on the single cell level, I aimed to establish
protocols by which global levels of histone modifications can be determined for individual
cells and for marked subpopulations.
5.1.1 Detection of nuclear antigens
In order to have access to the desired antigens within the chromatin inside the nucleus, differ-
ent fixation and permeabilization approaches with variations in their harshness were tested.
In total, 3 different methods were applied: fixation in 4% formaldehyde and permeabilization
by saponin-supplemented buffers, fixation and permeabilization in ice-cold alcohol or fixation
and permeabilization by formamide and heat. It turned out that different antibodies require
different fixation strategies for successful staining. Two protocols were sufficient to cover all
antibodies used. In summary, all antibodies and the corresponding protocols are listed in
Table 5.1. For intranuclear staining cells were fixed and permeabilized prior to incubation
with primary and secondary antibodies. In order to test for unspecific signals produced by
background staining, cells were subjected to flow cytometric analysis with or without fixation
as well as with or without primary antibody incubation. Figure 5.1 A shows that only fixed
and permeable cells which were incubated with primary and secondary antibodies exhibited
increased fluorescence signals over negative control levels. This indicates that the primary
antibody recognizes intracellular antigens only and that the secondary antibody had neither
inside nor outside the cell unspecific affinities.
Table 5.1: Antibodies used for chromatin flow cytometry.
Specificity Species, isotype Company
Order
number
Antibody per 100 µl
staining solution [ng]
Protocol
H3 rabbit, polyclonal Abcam ab1791 600 A, B
H3K4me3 rabbit, polyclonal Abcam ab8580 500 A, B
H3K27me3 mouse, IgG3k Abcam ab6002 1,000 B
H3K27me3 rabbit, polyclonal Diagenode CS-069-100 250 A, B
H3K9me2 mouse, IgG2ak Abcam ab1220 250 A, B
H3K9ac rabbit, polyclonal Abcam ab10812 100 A, B
H3K9/14ac
(pan-acH3)
rabbit, polyclonal Upstate 06-599 500 A
H4 rabbit, polyclonal Upstate 07-108 1,000 A, B
H4K8ac rabbit, polyclonal Upstate 06-760 250 A, B
H412ac rabbit, polyclonal Upstate 06-761 250 A, B
H416ac rabbit, polyclonal Upstate 06-762 250 A, B
H4K5/8/12/16ac
(pan-acH4)
rabbit, polyclonal Upstate 06-598 250 A, B
Isotype control rabbit, polyclonal Dianova rabpolypureisotc 250 A, B
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To further prove that the fluorescence signals were indeed located inside the nucleus, cytospin
samples of chromatin flow cytometrically stained cells were prepared, DNA was counter-
stained with Hoechst 33258 and the subcellular distribution of staining signals was examined.
As displayed in Figure 5.1 B signals of immunofluorescently stained histone modifications
were exclusively located inside the nuclei.
Figure 5.1: Chromatin flow cytometry detects nuclear antigens in ES cells. A) Analysis of ES cells
with secondary, isotype control or anti-H3K9ac antibodies. Primary antibodies were detected by anti-rabbit
secondary antibodies (phycoerythrin, PE). ES cells were incubated without fixation in FACS buffer or cells
were fixed and permeablized (protocol A). Histogram showing PE fluorescence intensities and percentages of
positive cells. B) Fixed ES cells were immunofluorescently stained with H3K9ac-specific antibody using flow
staining procedures. Cells were cytospun and DNA was counterstained (Hoechst 33258). One representative
analysis of 3 individual experiments is shown.
5.1.2 Specificity of measurement
To prove that the chromatin flow cytometry approach specifically displays epitopes, firstly
I analyzed ES cells prior and post treatment with the HDAC inhibitor TSA (Figure 5.2
A). As HDAC inhibition results in histone hyperacetylation, cells were immunofluorescently
stained with an antibody specific for H4K16ac. Flow cytometric analysis revealed an increase
in global H4K16ac levels in TSA-treated cells, while histone H4 signals, used as a control,
remained unchanged. A similar increase in H4 acetylation signal was verified by Western blot
analysis. TSA-induced histone hyperacetylation was detected with all antibodies recognizing
acetylated lysine residues listed in Table 5.1 (data not shown).
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Secondly, trimethylation levels of H3K27 were analyzed in EED KO and in wild type ES cells
(Figure 5.2 B). EED KO ES cells lack a critical component of the PRC2 that is involved in
the methylation of H3K27 [131]. Flow analysis of EED KO and of wild type ES cells clearly
showed a reduction of global H3K27me3 levels in EED KO as compared to wild type cells,
whereas the H3 signal persisted at unchanged levels. The reduction in H3K27me3 signal was
also seen in Western blot analyses.
Together, the data show that chromatin flow cytometry specifically detects nuclear antigens
in ES cells.
Figure 5.2: Chromatin flow cytometry specifically detects histone modifications. A) Flow cyto-
metric (top) and Western blot (bottom) analysis of ES cells +/- TSA (9 h, 150 nM) stained with H4K16ac-
and H4-specific antibodies. Representative analyses are shown (flow cytometry, n = 4; Western blot, n = 3).
B) Flow cytometric (top) and Western blot (bottom) based comparison of wild type and EED KO ES cells
with H3K27me3- or H3-specific antibodies. Representative analyses are shown (flow cytometry, n = 4; Western
blot, n = 2).
5.1.3 Studies on histone modification levels in differentiating ES cells
Flow cytometry in general allows the simultaneous analysis of multiple parameters. To make
use of this advantage I combined the detection of a cell surface marker with the assessment of
an intranuclear histone modification level. Upon differentiation mouse ES cells lose the surface
marker SSEA1 [32]. V6.5 ES cells were differentiated for 7 days as EBs in the presence of
0.1 µM all trans retinoic acid (ATRA) and subsequently singularized, fixed and double stained
for extracellular SSEA1 levels and the H3K9ac histone modification. As depicted in Figure
5.3, about 75% of the differentiated ES cells showed low levels of SSEA1 whereas only 20%
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were SSEA1positive. Electronic gating of SSEA1positive and SSEA1negative cells, respectively,
revealed that the H3K9ac level was higher in the SSEA1positive subpopulation than in the
SSEA1negative cells. Histone H3 levels, however, were similar in the two subpopulations.
In summary, these data show that chromatin flow cytometry allows the simultaneous detection
of surface and intranuclear antigens and that different global chromatin modification levels
can be distinguished in individual cells of heterogeneous, differentiating ES cell populations.
Figure 5.3: Chromatin flow cytometry detects altered histone modification levels upon ES cell
differentiation. Flow cytometric analysis of surface marker SSEA1 and intranuclear H3K9ac (top) or H3
(bottom) levels in 7 days differentiated ES cell cultures. SSEA1positive and SSEA1negative cells were gated
(left) and plotted in histogram overlays according to H3K9ac levels (right). One representative analysis of 3
individual experiments is shown.
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5.2 Analyzing the effect of HDAC inhibition on the hematopoietic
potential of BM cells
The chromatin and epigenome of pluripotent ES cells and of multipotent adult stem cells,
like HSCs, mirrors their capability to self renew and to differentiate. In the scope of this
thesis, I analyzed histone acetylation in BM cells and the effect of TSA treatment on the
hematopoietic activity of BM cells.
5.2.1 Global histone acetylation in BM cells
By applying chromatin flow cytometry in combination with lineage marker antibodies, which
recognize macrophages, granulocytes, erythrocytes, T- and B-lymphocytes, I compared global
levels of pan-acetylated histone H4 (pan-acH4) in the immature Lin− population, including
HSCs, to mature Lin+ cells. As shown in Figure 5.4 A, pan-acH4 levels in Lin− and Lin+
cells were similar. However, if treated with the HDAC inhibitor TSA, global pan-acH4 levels
were elevated whereas H3 levels remained unchanged (Figure 5.4 B).
In order to measure not only histone acetylation levels but also the activity of HDAC enzymes,
an HDAC activity assay was performed on nuclear extracts of either Lin+ or Lin−/int BM cells
which were separated by MACS technology. The results obtained from this colorimetric assay
are depicted in Figure 5.4 C. As expected, nuclear extracts of BM cells pretreated with TSA
showed significantly reduced HDAC activity levels. As the majority of unfractionated BM
cells consists of lineage committed Lin+ cells, the HDAC activity of whole BM extracts and
Lin+ cells were on a comparable level. However, the Lin−/int BM cells exhibited a significantly
elevated HDAC activity with a more than 1.5-fold increase.
Together, these data show that the executing enzymes that remove acetyl-groups from histones
are more active in the uncommitted Lin−/int compartment. However, this has no consequences
on global histone acetylation states.
5.2.2 Effect of TSA treatment on in vitro and in vivo hematopoietic activity
Treatment with the HDAC inhibitor TSA was previously shown to expand CD34+ human
umbilical cord blood cells with hematopoietic repopulating activity [68]. Therefore, I aimed to
analyze whether TSA treatment would also affect hematopoietic activity of mouse BM cells.
For the analysis of TSA treatment effects on in vitro and in vivo hematopoietic activity, BM
cells were cultured ex vivo in medium supplemented with IL3, IL6 and SCF for two days in
the absence or presence of increasing concentrations of TSA. Subsequently cells were placed
into in vitro and in vivo assays to estimate their hematopoietic activity.
First, freshly isolated and cultured BM cells were subjected to a flow cytometric analysis in
order to obtain information about the frequency of LKS cells, which comprise HPSCs. The
analysis revealed that the percentage of LKS cells increased slightly during a 2-day culture
period from 1.25% to 2.72% (Figure 5.5 A). However, increasing concentrations of TSA could
raise the LKS cell frequency to more than 18%, which is a 10-fold increase as compared to
freshly isolated BM cells. Also VPA, another HDAC inhibitor, showed similar effects on the
percentage of LKS cells.
The influence of TSA treatment on cell numbers was examined by counting living cells before
and after treatment and culture. Figure 5.5 B (left panel) displays the decline of living cells
with increasing concentrations of TSA. Less than 10% of the initially plated cells were alive af-
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Figure 5.4: Lin− and Lin+ BM cells have similar histone H4 acetylation levels, but different
HDAC activities. A) Histone H4 acetylation status of electronically gated Lin+ and Lin− BM subpopulations
analyzed by pan-acH4- (left) and H3- (right) specific intranuclear flow cytometry. A representative analysis
of three independent experiments is shown. (B) Histone H4 acetylation status of BM cells cultured with or
without TSA. Fresh BM cells were cultured for 4 h with/without 150 nM TSA and stained with pan-acH4-
(left) and H3- (right) specific antibodies for flow cytometry. C) HDAC activity in nuclear extracts of separated
Lin−/int and Lin+ BM cells by a fluorimetric HDAC activity assay. A TSA-treated extract is shown as
control. Normalized means and standard deviations of HDAC activities are plotted. From three individual cell
separation procedures and sample preparations, a total of nine measurements was obtained for each cellular
fraction. Including correction for multiple testing, statistical significance had a level of P < 0.005.
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ter a 2-day treatment period with 50 nM of TSA. By subjecting BM cells to a methylcellulose
(MC)-based colony formation assay the relative colony forming capacity, which reflects HPC
activity, was determined. The number of colonies which formed from 5,000 cells increased in
BM cells which were cultured and treated with 50 nM TSA (Figure 5.5 B, middle). However,
as only few cells survived 50 nM TSA treatment, the corresponding absolute number of CFCs
was less in 50 nM TSA-treated than in 5 or 10 nM TSA-treated cultures (Figure 5.5 B, right
panel). In order to measure more primitive HPCs, a secondary CFC assay was performed by
plating primary into secondary MC cultures. Compared to untreated or 10 nM TSA-treated
cells, BM cells which were treated with 50 nM TSA formed 6-fold more secondary colonies
(Figure 5.5 B, lower panel).
As the proof of in vivo repopulation of irradiated recipients is the most stringent test of
HPSCs, 20,000 freshly isolated and in parallel cells cultured for 2 days +/- TSA were trans-
planted into lethally irradiated mice. Peripheral blood was analyzed for donor cell contribu-
tion 16 weeks after transplantation. Cultured and TSA-treated BM cells were derived from
the Ly5.1 mouse strain, whereas recipients and co-transplanted competing BM cells carried
Ly5.2 leukocyte antigens. Flow cytometric analysis for Ly5.1+ cell frequencies in the periph-
eral blood showed that the donor contribution decreased 4-fold from 20% to 5% when BM
cells were ex vivo cultured for 2 days (Figure 5.5 C). Importantly, mice that received 50 nM
TSA-treated BM cells possessed an average of 50% of donor cells in their peripheral blood.
These data indicate that upon 50 nM TSA treatment the relative frequency of phenotypical,
in vitro colony forming and in vivo repopulating HPSCs is increased, though high TSA con-
centration caused more than 90% of cell death. A net expansion of HPCs with in vitro colony
forming potential could only be determined for BM cells treated with low concentrations of
TSA.
5.2.3 Selective cell survival upon TSA treatment
To address the question of whether TSA affects differentiation and selectively induces cell
death, freshly isolated BM cells were separated with respect to their grade of lineage com-
mitment into Lin+ and Lin−/int subpopulations by MACS. Separated cell populations were
cultured for 2 days with growth factors in the absence or presence of TSA. As shown in Fig-
ure 5.6 A, in the two separated subpopulations cell numbers declined upon TSA treatment,
however, more cells of the Lin−/int subpopulation survived.
Additionally, I examined the cultured and treated Lin−/int subpopulation regarding apoptosis
and Lin marker expression. Figure 5.6 B illustrates a representative flow cytometric analysis.
Lin−/int cells gained Lin marker surface expression during a 2-day culture period without
TSA, suggesting commitment and differentiation. However, the frequency of Lin+ cells was
reduced in a dose-dependent manner when cells were treated with TSA (Figure 5.6 B, C).
The analysis further revealed that treatment with 50 nM TSA resulted in a higher proportion
of Lin− cells within the living (AnnexinVnegative) cell population (Figure 5.6 B, D).
Together, this indicates that TSA treatment induces apoptosis preferentially in Linint and in
Lin+ cells.
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Figure 5.5: HDAC inhibition by TSA results in higher frequencies of in vitro and in vivo
HPSCs. Analyses were done with either freshly isolated BM cells or with BM cells cultured for 2 days in
medium supplemented with IL3, IL6 and SCF with or without HDAC inhibitors. A) The results of c-Kit-
and Sca1-specific FACS analyses of gated Lin− cells of fresh BM and BM cells cultured for 2 days either with
or without increasing concentrations of TSA or VPA are shown. A representative analysis is shown. Lin−,
c-Kit+ and Sca1+ (LKS) cell frequencies are indicated (gates); n=4. B) Total cell numbers of BM cultures
are displayed directly after plating (fresh) or after 2 days of treatment with increasing amounts of TSA or
VPA. Also shown are CFC frequencies per 5,000 cells and absolute CFC numbers [absolute CFC number =
(CFC numbers/5,000 cells) / cell number of day-2 cultures). Cells were cultured for 2 days in the absence
or presence of TSA or VPA. Living cells were counted by trypan blue staining and equal cell numbers were
seeded into methylcellulose (MC) medium. Colony numbers were counted after 10 days of culture. Mean values
and standard deviations are shown (n=5). Secondary CFC frequencies in untreated and treated BM cultures
(bottom). BM cells were cultured for 2 days in either the absence or presence of TSA; then equal numbers of
living cells were seeded in MC medium. On day 10, colony frequencies were determined, followed by isolation
of cells from primary cultures. Equal cell numbers were re-plated into secondary MC cultures. Colony numbers
of secondary cultures were counted at day 10 post plating. Mean values and standard deviations are displayed
(n=3). C) Engraftment potential of TSA-treated BM cells. Donor reconstitution of irradiated mice with fresh
BM cells or BM cells cultured with or without TSA. Ly5.1 BM cells were cultured for 2 days in the absence
or presence of TSA. Cells were injected into irradiated Ly5.2 recipients together with Ly5.2 competitor BM
cells. Peripheral blood cells of transplant recipients were analyzed by flow cytometry for the presence of donor
(Ly5.1) and recipient cells 16 weeks post transplantation. Percentages of Ly5.1 donor cells are indicated.
Analyses are shown from two independent experiments comprising eight recipients per cell sample. Mean
values and standard deviations are indicated. Including correction for multiple testing, statistical significance
had a level of P < 0.005.
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Figure 5.6: TSA treatment preferentially kills mature BM cells. A) Cell numbers of MACS-
separated Lin+ and Lin−/int BM cells are shown after 2 days of culture with/without TSA (n=3). B) Flow
cytometric analysis of Lin−/int BM cells directly after MACS separation (fresh) and after 2 days of culture
(untreated, 10 nM, 50 nM TSA). Cells were analyzed for Lin expression and for apoptosis (by AnnexinV
staining). Gates (Lin−, Linint, Lin+) were defined according to unstained and Lin+ MACS-separated BM
cells. A representative analysis is shown (n=3). C) Percentages of Lin+ cells and D) percentages of Lin− cells
within the alive, AnnexinVnegative cell population. Data in C and D were taken from the plot shown in B.
The total number of AnnexinVnegative cells was always set to 100% (C, D).
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5.3 Studying differentiation of pluripotent mouse ES cells
Pluripotent mouse ES cells are in vitro derivatives of ICM cells from murine E3.5 preimplan-
tation blastocysts. ES cells can be maintained infinitely as stable cell lines that self renew
without losing differentiation potential [6]. The presence of LIF and feeder cells in standard
ES cell culture conditions activates the transcription factor network including Oct4, Sox2 and
Nanog which maintains ES cells in a groundstate of pluripotency [155, 156]. By differentiation
induction, either in vitro or in vivo, pluripotent ES cells can give rise to cell types of all three
germ layers and germ cells. The following section contains analyses on early steps of in vitro
ES cell differentiation induced by the withdrawal of LIF and feeder cells.
5.3.1 Differentiation potential of different ES cell lines
Here I aimed to analyze the loss of pluripotency in mouse ES cells which were differentiated
as EBs. Distinct ES cell lines underlie clonal variation which is reflected by different cellular
reactions upon differentiation induction. Thus, in order to minimize observations that are
based on cell line-specific properties, the differentiation experiments were performed with 3
different ES cell lines. D3 ES cells (129/Sv X 129/Sv) were grown on gelatin-coated tissue
culture (TC) dishes [157], whereas V6.5 (129/Sv X C57BL6) and OG2 (CBA X C57BL6) ES
cells were regularly grown on MEF feeder layers [42, 158]. For EB formation 1,000 ES cells
were clustered to one EB per hanging drop (HD) in differentiation medium (Scheme 5.1).
EBs were cultured for up to 7 days. Figure 5.7 A shows light microscopic pictures of the ES
cells and the corresponding EBs. At individual days defined numbers of EBs were harvested,
dissociated, cells were counted and cell numbers per EB were determined (Figure 5.7 B). Also
the diameters of EBs were measured microscopically, results are given in Figure 5.7 C.
During differentiation the 3 ES cell lines showed different proliferation behaviors, which was
reflected by differences in the cell numbers per EB and EB size differences. D3 cells divided
most rapidly but during the last 2 days of differentiation they failed to continue to proliferate,
as the EB size decreased and the cell numbers remained unchanged. In contrast, V6.5 and
OG2 cells proliferated continuously. The maximum diameter of D3 EBs was accomplished at
day 5. This diameter was comparable to the maximum diameter of OG2 EBs at day 7. Thus,
due to faster proliferation, D3 EBs reached a maximal size earlier. A maximal EB size might
be limited to a diameter that still allows sufficient diffusion of nutrients.
A marker of pluripotent ES cells is SSEA1 on the cell surface [32, 159, 160]. In Figure 5.8 flow
cytometric data are depicted reflecting the relative frequencies of SSEA1high, SSEA1medium,
SSEA1low and SSEA1negative cells within ES and EB cells of the 3 lines. As the expression of
SSEA1 is fluctuating within a certain range in ES cell cultures [32], ES cells (day 0 of differen-
tiation) of all 3 lines showed medium and high SSEA1 expression, as expected. Interestingly,
clustering of 1,000 ES cells to one EB for 1 day increased the proportion of SSEA1high cells
2-fold. Steadily, SSEA1 levels declined during proceeding differentiation and at day 4 cells
reached SSEA1 levels similar to undifferentiated ES cells. However, after 7 days of differen-
tiation SSEA1 levels differed among the 3 lines. While most OG2 and V6.5 ES cell-derived
cells showed medium SSEA1 levels, most D3 cells were SSEA1low.
These data suggest, that (i) SSEA1 is not a stringent marker for pluripotency, because its
levels decline late during differentiation, that (ii) the fluctuation towards SSEA1high levels are
favored during early differentiation and that (iii) different ES cell lines vary in their dynamics
of SSEA1 down-regulation.
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Figure 5.7: D3, OG2 and V6.5 wild type ES cells have different proliferation kinetics upon EB
differentiation. A) Light microscopic photographs of undifferentiated D3, OG2 and V6.5 ES cells (day 0;
d0) and differentiated EBs (day 2 to day 7; d2-7). In each case 1,000 ES cells were clustered to one EB by
HD differentiation procedure for 2 days, cells were subsequently maintained in suspension culture. B) Cell
numbers per EB are shown for the 3 cell lines at the indicated days of differentiation. Defined numbers of
EB were harvested, dissociated and cell numbers were determined (n=3). C) Diameters of EBs at day 2-7 of
differentiation were obtained by software analyses of microscopic pictures (n=3).
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Besides the cell surface marker SSEA1, expression of a set of pluripotency- and differentiation-
associated genes was analyzed (Figure 5.9). Unexpectedly, for all cell lines the expression of
pluripotency-associated genes was up-regulated in 1-day differentiated cells versus ES cells,
before levels declined at day 7 of differentiation. I did not observe a clear and steady down-
regulation but rather slight reduction with considerable fluctuation. V6.5 cells showed still
highest expression levels of Oct4, Sox2, Rex1 and Nanog after 7 days of differentiation as
compared to the other 2 ES cell lines, while almost no endodermal AFP transcription could
be detected. OG2 cells immediately and exclusively expressed AFP at day 1, whereas D3
cells expressed the endodermal marker after more than 4 days. In contrast, the mesodermal
differentiation analyzed by Bry gene expression started early and strongly in D3 cells, while
in OG2 and V6.5 cells, Bry was detected at day 7. The ectodermal lineage, measured by
Nestin expression, appeared in all cell lines at day 4 with a maximum expression. OG2 cells
expressed highest levels of Nestin.
Together, while pluripotency marker genes were still found to be expressed after 4 and 7 days
at levels comparable to undifferentiated ES cells, ecto-, meso- and endoderm-associated mark-
ers were up-regulated reflecting ongoing differentiation. Simultaneous detection of markers
for undifferentiated cells and differentiated cells could be the result of mixed heterogeneous
cell populations.
ES cells have the capability to self renew while maintaining their pluripotent character and
to differentiate to all embryonic cell lineages upon differentiation induction. Here, it was
analyzed how fast these features were lost during in vitro differentiation in 3 different ES cells
lines.
ES cells self renew by forming clonal colonies under standard ES cell culture conditions. In
a colony forming assay the potential of ES and EB cells to form colonies with alkaline phos-
phatase (AP) activity was compared. Figure 5.10 A displays the percentage of self renewing
CFCs in ES cell cultures and among differentiated EB cells. All 3 lines showed declining
frequencies of CFCs with proceeding differentiation times, indicating a loss of self renewal
capacity. Especially during the first 2 days of differentiation the frequency of CFCs dropped
to approx. 30%. Notably, the potential to form colonies differed in the 3 undifferentiated ES
cell cultures. The percentage of CFCs varied from approx. 100% CFCs in D3 and OG2 ES
cells to only 40% in V6.5 ES cells.
By performing EB formation assays I next compared the potential of the 3 ES cell lines and
their differentiated EB cells to proliferate under differentiation conditions in MC. Therefore,
feeder-free ES cells or dissociated EB cells after 1 to 7 days of differentiation were plated into
semisolid medium without LIF to allow clonal proliferation yielding EBs. The 3 ES cell lines
varied in their EB formation frequency: 140 out of 1,000 D3 ES cells developed EBs, 100 of
1,000 OG2 ES cells formed EBs. Only 60 EBs developed per 1,000 V6.5 ES cells (Figure 5.10
B). Despite these dissimilarities the frequency of EB forming cells declined during differenti-
ation in all 3 lines. OG2 and V6.5 cells reached a minimum of EB forming cells after 2 days
of differentiation, whereas in D3 cell cultures EB formation potential was still present after
3 days.
In order to analyze the differentiation potential towards spontaneously contracting cardiomy-
ocytes, I next applied the ’beating body’ assay to either ES cells or their differentiated progeny
[161]. Therefore, EBs were generated by the HD method and subsequently single EBs were
placed into wells of gelatin-coated 48-well plates. Contractile properties of individual EBs
were analyzed after 10 days by microscopy. Figure 5.10 C summarizes the frequency of con-
tracting EBs which were formed by undifferentiated ES or by differentiated EB cells. Again
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Figure 5.8: SSEA1 surface expression is slowly diminished upon EB differentiation. Undifferen-
tiated ES cells (d0) and differentiated EB cells harvested at days 1, 2, 3, 4 or 7 of differentiation were stained
with primary SSEA1-specific and subsequently with secondary anti-mouse-Cy3 antibodies. Shown are repre-
sentative flow cytometric histogram plots with corresponding gate frequencies for SSEA1negative, SSEA1low,
SSEA1medium and SSEA1high subpopulations (n=3).
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Figure 5.9: Gene expression in D3, OG2 and V6.5 ES cells during EB differentiation. RNA
was prepared from undifferentiated ES cells (d0) or differentiated EB cells harvested at days 1, 2, 3, 4 or 7 of
differentiation. cDNA was synthesized and realtime PCR was performed with primers specific for pluripotency
genes (Oct4, Rex1, Nanog, Sox2) or for ecto-, meso- and endodermal markers (Nestin, Bry, AFP) as well as
for EED.
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Scheme 5.1: In vitro differentiation methods for murine ES cells. ES cells form EBs by clustering in
hanging drops (HD) or by clonal proliferation in a semisolid methylcellulose (MC) medium. When attached
to tissue culture (TC) surface ES cells also differentiate as monolayer (ML) cells.
the 3 undifferentiated ES cell lines differed in their efficiency to generate ’beating bodies’.
All EBs formed by D3 and V6.5 ES cells contained contracting cells, whereas only 20% of
the OG2 ES cell-derived EBs were contracting. Interestingly, in V6.5 and OG2 cells the
potential to differentiate to cardiomyocytes was lost after 1 and 2 days of differentiation in-
duction, respectively. For D3 cells, which were differentiated for 3 days and subsequently
subjected to the ’beating body’ assay, no contracting cardiomyocytes were observed anymore.
However, in 4-day and 7-day differentiated D3 EB cells there were 40% and 10% of wells
containing contracting EBs. Maybe after 4 or 7 days of differentiation first progenitors of
cardiomyocytes appeared in D3 EB cultures. Hence, if subjected to the ’beating body’ assay,
previously differentiated cardiomyogenic cells could induce contraction. Cardiomyocytes are a
mesoderm-derived cell type and gene expression analysis of the mesoderm inducer brachyury
(Bry) revealed unexpectedly early expression in the course of D3 ES cell differentiation (Fig-
ure 5.9). This indicates a favored mesodermal lineage commitment and fits to the overall high
efficiency of ’beating body’ formation (Figure 5.10).
Altogether, these assays showed that the self renewal and differentiation capacity of ES cells
decreased when cultured under differentiation conditions for 3 days. However, individual
ES cell lines behaved differently with regards to their colony and EB formation capacity,
especially in the undifferentiated state.
5.3.2 Progression of differentiation as a consequence of differentiation method
Differentiation of mouse ES cells is generally induced by withdrawal of LIF and feeder cells
from culture conditions. Different methods of differentiation were described in the litera-
ture and in the scope of this thesis I focused on 3 distinct protocols, which are summarized
in Scheme 5.1 [49]. ES cells can be clustered by gravity in HDs of differentiation medium,
yielding EBs of similar size. EBs can also be formed from single ES cells in semisolid MC
differentiation medium, avoiding stochastic aggregation and resulting in clonal-derived EBs
[162]. Alternatively, ES cell differentiation can be induced by culturing ES cells as an adher-
ent ML on TC plastic surfaces in differentiation medium [51].
In order to compare the impact of the differentiation method on the loss of pluripotency I
measured eGFP levels in OG2 cells which express eGFP under the control of a transgenic
distal Oct4 enhancer that is active in ICM and ES cells [158]. Figure 5.11 shows a flow
cytometric analysis of Oct4-eGFP expression in undifferentiated OG2 ES cells and in differ-
entiated EB cells. EBs were either formed clonally in MC or by clustering in HDs. Oct4-eGFP
levels started to decrease at the 3rd day of differentiation. However, at day 4 and 7 it became
obvious that EB cells in MC steadily and homogeneously lost Oct4-eGFP expression, whereas
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Figure 5.10: D3, OG2 and V6.5 ES cells lose functional properties of pluripotency upon HD EB
differentiation. A) Undifferentiated ES (d0) and EB cells after 1, 2, 3, 4 or 7 days of in vitro differentiation
were reseeded into ES cell culture conditions. Developing colonies were stained for AP activity and colonies
were counted. Displayed are the percentages of CFCs for the respective days of differentiation and for the 3
cell lines (n=3). B) Undifferentiated ES (d0) and EB cells after 1, 2, 3, 4 or 7 days of differentiation were
plated into MC medium to determine clonal EB formation capacity. Shown are the numbers of EBs formed
of 1,000 cells seeded at the given days of differentiation and for the 3 cell lines (n=3). C) Undifferentiated
ES (d0) and EB cells after 1, 2, 3, 4 or 7 days of differentiation were used as initial cellular material for a
’beating body’ assay. Frequencies of contracting EBs were enumerated after a total of 15 days (2 days HD,
3 days suspension, 10 days attached EBs), percentages are depicted (n=1).
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HD EB cells split up to heterogeneous subpopulations of cells with no Oct4-eGFP expression,
medium and high levels of Oct4-eGFP.
Further the localization of Oct4-eGFPhigh cells within 7-day old HD EBs was investigated
by cryosectioning and fluorescence microscopy. The analysis revealed that a couple of Oct4-
eGFPpositive cells were located particularly in the center of the EB and formed islet-like
clusters (Figure 5.12).
Similarly to EB differentiation, OG2 ES cells which were differentiated as ML started to
exhibit reduced Oct4-eGFP levels at day 3 (Figure 5.13). However, the uniformity and pro-
gression of differentiation seemed to depend on the density of cells within the ML, i.e. the
degree of confluence. Starting with less ES cells resulted in more uniformly differentiated cells
at day 6, while high initial cell numbers gave rise to subpopulations of cells with no and with
high Oct4-eGFP levels. Light microscopic imaging of high density seeded ML differentiation
cultures revealed colony-like structures of cells growing on a confluent layer of differentiated
ES cells, as shown in Figure 5.14. Indeed, the colony-like nests of cells turned out to be
eGFPpositive whereas the layer underneath appeared less intense in fluorescence (data not
shown).
In summary, these results show that - as evidenced by Oct4-eGFP expression - differen-
tiation proceeded more efficiently and uniformly when ES cells started the differentiation
process isolated and not in close proximity to other ES cells. This suggests an influence of
the microenvironment provided by (differentiating) ES cells on the loss of pluripotency.
5.3.3 Reversibility of Oct4-eGFP expression after differentiation-induced loss
Previously it was reported that the levels of some pluripotency-associated proteins are fluc-
tuating in ES cells without affecting pluripotency [34]. Besides Rex1, Stella and SSEA1 also
Nanog levels are subjected to fluctuations, most probably as a result of a reversible shift
between embryonic stem cell and epiblast stem cell identity [32, 33, 34, 35, 36]. Alternating
levels of Oct4 RNA or protein were so far not shown. Therefore I aimed to examine whether
differentiated ES cells with reduced Oct4-eGFP expression levels can regain ES cell expression
levels of Oct4-eGFP under standard ES cell culture conditions. For this purpose I differen-
tiated OG2 ES cells for 3 days as HD EBs until about half of the cells showed Oct4-eGFP
signals clearly below ES cell levels. Cells of dissociated EBs were sorted by FACS with respect
to their eGFP fluorescence intensity into an Oct4-eGFPhigh and Oct4-eGFPmedium subpopu-
lation. Separately, sorted cells were cultured under ES cell conditions and Oct4-eGFP levels
were analyzed (Figure 5.15, 5.16 and Scheme 5.2).
Figure 5.15 gives the percentages of Oct4-eGFPhigh, Oct4-eGFPmedium, Oct4-eGFPlow and
Oct4-eGFPnegative populations in undifferentiated ES cells, in 3 days differentiated EB cells
as well as in sorted EB cells, respectively. After FACS-sorting Oct4-eGFPmedium and Oct4-
eGFPhigh cells were cultured for 4 and 6 days under standard ES cell conditions. As HDAC
inhibitors were reported to have a beneficial effect on reprogramming efficiency of Oct4negative
MEFs to Oct4positive iPS cells, I additionally treated differentiated cells with 20 nM TSA dur-
ing the first 24 h of ES cell culture [100]. The experiment revealed that differentiated EB
cells with medium Oct4-eGFP expression levels after 4 days in ES cell culture continued to
lose Oct4-eGFP expression as more than 80% of cells were Oct4-eGFPnegative. However, the
subpopulation of Oct4-eGFPhigh cells increased from 0.5% immediately after sorting to 2.9%
in the untreated culture and to 8.6% upon TSA treatment. After 6 days of ES cell culture
conditions the frequency of Oct4-eGFPhigh cells increased to 30.3% in the absence and to
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Figure 5.11: EBs derived from clustered ES cells exhibit a higher grade of cellular heterogeneity
than single cell-derived EBs. Oct4-eGFP levels of undifferentiated OG2 ES cells (d0) and differentiated
cells were flow cytometrically determined. Levels are shown as histogram plots with gate frequencies for
eGFPnegative, eGFPmedium and eGFPhigh subpopulations. ES cells were either differentiated in semisolid MC
(left panel) or as clustered EBs in hanging drops (HD, right panel). A representative analysis of two individual
experiments is given.
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Figure 5.12: Subpopulations of Oct4-eGFPpositive cells are located in central regions of EBs and
form clusters. OG2 ES cells were differentiated for 7 days as HD EBs. EBs were embedded, frozen and
sectioned. Nuclei were visualized by DAPI staining. Magnification: 10x.
67.1% in the presence of TSA, respectively. Differentiated cells which had been sorted for
high eGFP levels also showed some Oct4-eGFPmedium, Oct4-eGFPlow and Oct4-eGFPnegative
cells after 4 days, indicating ongoing differentiation. Again the transient TSA treatment led
to larger proportions of Oct4-eGFPhigh cells. This became even more evident after 6 days
of culture when 87% of the cells became Oct4-eGFPhigh. Also the fluorescence intensity was
increased (shown by the right-shifted peak).
Together, two observations were notable from this analysis: firstly, though most of the Oct4-
eGFPmedium cells lost Oct4-eGFP expression during 4 days in ES cell culture, some cells
maintained high Oct4-eGFP expression levels. The proportion of Oct4-eGFPhigh cells in-
creased after a total of 6 days post sort. This could be the result of re-gaining of Oct4-eGFP
expression by cells that were Oct4-eGFPnegative or it was the result of a selective expansion
of Oct4-eGFPhigh cells deriving from a contamination with undifferentiated ES cells during
the FACS-sort procedure. Secondly, a transient TSA treatment of differentiated ES cells led
to higher frequencies of cells with high Oct4-eGFP expression, which might be due to either
a reprogramming effect or to selective survival of a contaminating Oct4-eGFPhigh subpopu-
lation.
Though the purity of the sorted cell populations after FACS appeared to be high, I decided
to ascertain whether contamination with eGFPhigh cells in the sorted eGFPmedium samples
was the reason for cells with high levels of Oct4-eGFP expression. For this purpose, different
numbers of 3 days differentiated and sorted eGFPmedium OG2 cells were plated into ES cell
culture conditions. As displayed in Figure 5.16 A, after sorting there was a contamination
with Oct4-eGFPhigh cells of only 0.56%, suggesting that about 1 out of 200 cells was Oct4-
eGFPhigh. Sorted cells were plated at the following concentrations: 100, 200, 400, 800, 1,600
and 3,200 cells per plate. After 2, 4 and 6 days flow cytometric analyses were done to control
for Oct4-eGFP expression levels. Figure 5.16 B (untreated cells) summarizes the frequencies
of Oct4-eGFPhigh, Oct4-eGFPmedium, Oct4-eGFPlow and Oct4-eGFPnegative cells according
to the gates shown in Figure 5.16 A. After 2 days analyses showed that the more cells had been
plated out, the larger was the proportion of Oct4-eGFPlow/medium/high cells. Also the fraction
of Oct4-eGFPhigh cells increased from day 2 to day 6 at all cell densities. Figures 5.16 C and D
give respective gate frequencies for cells that were treated for 24 h with the HDAC inhibitors
TSA or VPA. Compared to untreated cultures the overall frequency of Oct4-eGFPlow cells,
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Figure 5.13: ML differentiation cultures with confluence exhibit higher cellular heterogeneity
than low-density ML cultures. Oct4-eGFP transgene levels of undifferentiated OG2 ES cells (d0) and of
differentiated cells were flow cytometrically determined. Expression levels are shown as histogram plots with
gate frequencies for Oct4-eGFPnegative, Oct4-eGFPmedium and Oct4-eGFPhigh subpopulations. ES cells were
differentiated on TC-grade dish surfaces. Low density (left panel) cultures started with 1 · 105 cells for day 6
cultures, with 3 · 105 cells for day 3 cultures, with 5 · 105 cells for day 2 cultures or with 5 · 105 cells for day 1
cultures. High density (right panel) cultures started with 5 · 105 cells for day 6 cultures, with 6 · 105 cells for
day 3 cultures, with 1 · 106 cells for day 2 cultures or with >1 · 106 cells for day 1 cultures. (n=2).
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Figure 5.14: ML differentiation cultures with confluence establish multilayer, colony-like growth
properties. Light microscopic photographs of undifferentiated OG2 ES cells and of ES cells differentiated
under ML differentiation conditions at days 1 to 6. Low density (left panel) cultures started with 1 · 105 cells
for day 6 cultures, with 3 · 105 cells for day 3 cultures, with 5 · 105 cells for day 2 cultures or with 5 · 105 cells
for day 1 cultures. High density (right panel) cultures started with 5 · 105 cells for day 6 cultures, with 6 · 105
cells for day 3 cultures, with 1 · 106 cells for day 2 cultures or with >1 · 106 cells for day 1 cultures. (n=2).
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Figure 5.15: Transient TSA treatment affects the frequency of Oct4-eGFPpositive cells in dif-
ferentiated and rescued ES cell cultures. Flow cytometrically Oct4-eGFP levels of the following cells
were determined and plotted as histograms with gate frequencies of Oct4-eGFPnegative, Oct4-eGFPlow, Oct4-
eGFPmedium and Oct4-eGFPhigh cells: OG2 ES cells (ESC), HD EB cells after 3 days of differentiation prior
to sort (d3 EB) and immediately post sort (i.e. 0 days post sort, [dps]) for medium (left panel) and high (right
panel) eGFP levels. Also shown are Oct4-eGFPmedium and Oct4-eGFPhigh sorted cells after 4 and 6 days of
subsequent ES cell culture conditions (4 dps and 6 dps) without (untreated) or with (TSA) 24 h treatment
with 20 nM TSA.
46
5.3 Studying differentiation of pluripotent mouse ES cells
Scheme 5.2: Experimental strategy for reversibility of Oct4-eGFP expression. OG2 ES cells were
differentiated for 3 days as HD EBs. Next, EBs were dissociated and cells were FACS-sorted into Oct4-
eGFPmedium and Oct4-eGFPhigh cells. Different numbers of sorted cells were cultured in the absence or
presence of HDAC inhibitors under standard ES cell conditions for 2, 4 or 6 days before reanalysis for Oct4-
eGFP expression by flow cytometry.
but not of Oct4-eGFPmedium and Oct4-eGFPhigh cells was clearly reduced after 2 days of ES
cell culture. The more cells were cultured the less Oct4-eGFPnegative cells were detected after
2, 4 and 6 days. Interestingly, after 6 days of culture at the lowest cell number (100 cells) the
frequencies of Oct4-eGFPhigh cells were at comparable low levels in untreated, in TSA- and
in VPA-treated cell cultures. Further, the highest percentages of Oct4-eGFPmedium/high cells
were detected in HDAC inhibitor-treated samples with high cell number plateing.
These results indicate that Oct4-eGFPhigh cells were probably a result of contaminating, se-
lectively proliferating cells, because even after 6 days only few Oct4-eGFPpositive cells were
detected when started with 100 cells. Additionally, the low percentage of Oct4-eGFPpositive
cells in the 100 cells sample after 6 days suggests that HDAC inhibition did not lead to
reprogramming of Oct4-eGFPnegative cells to Oct4-eGFPpositive cells. It rather seems that
HDAC inhibition resulted in a selective killing of Oct4-eGFPlow cells which were virtually
absent upon treatment. In summary, it could not be explicitly shown whether Oct4-eGFP
expression can be re-established in differentiated ES cells, however, the analyses performed
indicate that ES cell culture conditions can not re-establish Oct4-eGFP expression in ES cells
which once had reduced their Oct4-eGFP levels.
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Figure 5.16: Cell numbers and HDAC inhibitor treatment have an effect on the frequencies
of Oct4-eGFPpositive cells in differentiated and rescued ES cell cultures. A) OG2 ES cells were
differentiated for 3 days as HD EBs and sorted for medium expression of Oct4-eGFP. Flow cyotmetric validation
of Oct4-eGFP levels and gate frequencies of negative, low, medium and high subpopulations are displayed. B,
C and D) Gate frequencies of Oct4-eGFPhigh, Oct4-eGFPmedium, Oct4-eGFPlow and Oct4-eGFPnegative cells
as defined in A) are summarized as bar diagrams. Different numbers of sorted cells were plated (100, 200, 400,
800, 1,600 and 3,200) and cultured under ES cell culture conditions. Cells remained either untreated (B) or
cells were treated in the first 24 h post plating with 20 nM TSA (B) or 2 mM VPA (C). Oct4-eGFP levels
were analyzed after 2, 4 and 6 days (d2, d4, d6).
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5.4 Investigating the role of the Polycomb group protein EED in
ES cells
Pluripotency is the central property of ES cells. It is lost when cells differentiate and become
lineage-committed. While the genetic information of a cell remains unchanged, epigenetic
mechanisms lead to altered chromatin states that affect gene expression and cellular function
[163, 164, 165, 166, 167]. In ES cells the opposing histone modifications H3K4me3 and
H3K27me3, which are simultaneously present at promoters of development-associated genes,
form bivalent chromatin domains [119, 168, 120]. The PRC2 with its HMT EZH2 catalyzes
the methylation of H3K27. The complex member EED is essential for a functional PRC2
complex [131] (Scheme 4.4). Here I analyzed the consequences of EED deletion on local and
global chromatin structure and on the differentiation capacity of ES cells.
5.4.1 Local and global histone modifications
As the deletion of EED was reported to result in derepression of PRC2-target genes, I aimed
to prove whether this was also true for the EED KO ES cells used in this study. To exclude
for clonal variation of gene expression levels two wild type and two EED KO ES cell lines
were analyzed in parallel. A customized real time PCR array with a panel of primers which
are listed in Table 5.2 was performed. The array provides primers for genes that are associ-
ated with pluripotency, with differentiation, with chromatin modifications and with general
cellular properties. Figure 5.17 shows the gene expression of two wild type and two EED
KO ES cell lines relative to the housekeeping gene HPRT. Data sets were normalized to V6.5
wild type cells. However, the expression of several bivalently regulated genes could not be
detected, because improper melting curves or Cp values did not allow analysis of the data (see
Table 5.2). Probably, primers or PCR conditions were not optimal, though reactions were
performed according to the manufacturer’s protocol. Further, while expression levels of the
two EED KO cell lines appeared to be similar, the two wild type ES cell lines exhibited varia-
tions for some genes, such as mixl1 or cdx2. Despite these limitations, it could be shown that
expression levels of the pluripotency-associated genes oct4, myc, tert, dppa4, stat3, flp1l1 and
ctr9 were not affected by EED KO, as reported previously (Figure 5.17 A). However, other
pluripotency genes were up-regulated in EED KO ES cells: klf4, kit, tbx3 and tcl1 (Figure
5.17 A).
As expected, EED KO ES cells did not express eed, but normal levels of ezh2 and suz12
were observed (Figure 5.17 D). Interestingly, transcripts of the PRC1 member bmi1 were up-
regulated in EED KO ES cells. Also expression levels of p16 from the Ink4a locus (Cdkn2a),
for which Bmi1 is a transcriptional repressor, were elevated (Figure 5.17 C, D). Unexpectedly
and in contrast to what was reported previously, an increase of expression (derepression)
for the development-associated genes sox21, b-catenin, nestin, chordin, foxj3 or nodal was
not observed (Figure 5.17 B). Further, transcript levels of pmaip1, which is a pro-apoptotic
member of the Bcl-2 familiy, were increased in EED KO ES cells, while no elevated apoptosis
rates were detected (Figure 5.17 D and data not shown).
Next, the effect of EED deletion was investigated on H3K27 trimethylation levels, as this
modification is catalyzed by the PRC2. Local H3K27me3 levels at the transcriptional start
sites (TSS) of differentiation-associated genes were analyzed by chromatin immunoprecipita-
tion (ChIP) in wild type and EED KO ES cells. Figure 5.18 depicts the relative enrichment
of the H3K27me3 modification at the TSS of sox21, bry, hoxa3 and pax5. In accordance to
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Table 5.2: SABiosciences customized gene expression PCR array.
Category Gene symbol GenRefSeq Synonym Analyzable*
Pluripotency
Pou5f1 NM013633 Oct34 yes
Sox2 NM011443 no
Zfp42 NM009556 Rex1 yes
Nanog NM028016 yes
Klf4 NM010637 yes
myc NM010849 c-myc yes
Sall4 NM175303 no
Tert NM009354 Telomerase yes
Dppa4 NM028610 yes
Kit NM021099 c-Kit yes
Tbx3 NM011535 yes
Tcl1 NM009337 yes
Stat3 NM011486 yes
Fip1l1 NM024183 yes
Ctr9 NM009431 yes
Esrrb NM011934 yes
bivalently regulated genes
Irx2 NM010574 no
Dlx1 NM010053 no
Nkx2.2 NM010919 no
Sox21 NM177753 yes
Zfpm2 NM011766 no
Pax5 NM008782 no
Lbx1 NM010691 no
Evx1 NM007966 no
Primitive endoderm
AFP NM007423 alpha fetoprotein no
Ctnnb1 NM007614 beta-catenin yes
GATA4 NM008092 no
Sox7 NM011446 no
Sox17 NM011441 no
Mixl1 NM013729 yes
GATA6 NM010258 no
Definitive endoderm
Foxa2 NM010446 no
FABP1 NM017399 fatty acid binding protein 1 no
FABP2 NM007980 fatty acid binding protein 2 no
Hnf1b NM009330 no
Ectoderm
Nes NM016701 Nestin yes
Nog NM008711 Noggin no
Tubb3 NM023279 beta-3-Tubulin no
Chrd NM009893 Chordin yes
FoxJ3 NM172699 yes
Otx2 NM144841 yes
Mesoderm
T NM009309 Brachyury yes
Gsc NM010351 Goosecoid yes
Acvr1 NM007394 Activin A receptor yes
nodal NM013611 yes
wnt3a NM009522 no
tgfb1 NM011577 TGF beta yes
bmp2 NM007553 no
tal1 NM011527 no
Chromatin modifiers
eed NM021876 yes
ezh2 NM007971 yes
suz12 NM199196 yes
bmi1 NM007552 yes
Ehmt2 NM145830 G9a yes
Kdm6b NM001017426 Jmjd3 yes
Kdm6a NM009483 UTX yes
Kdm5a XM359326 Jarid1a yes
HDAC1 NM008228 yes
Dnmt1 NM010066 yes
Dnmt3a NM007872 yes
Dnmt3b NM010068 yes
Smarca4 NM011417 BRG1 yes
Smarca2 NM011416 BRM no
Mll1 NM001081049 yes
Kdm1 NM133872 LSD1 yes
Suv39H1 NM011514 yes
Suv39H2 NM022724 yes
Kdm4c NM144787 Jmjd2c yes
Others
Tcf4 NM013685 yes
HoxA3 NM010452 no
Sub1 NM011294 PC4 yes
Cdx2 NM007673 yes
Trp53 NM011640 p53 yes
CDKN1A NM007669 p21 yes
Cdkn2a NM009877 p16INK4a yes
cdk2 NM016756 yes
Pcgf6 NM027654 yes
Pcgf1 NM197992 yes
Nsd1 NM008739 KMT3b yes
Tcf15 NM009328 yes
Pmaip1 NM021451 Noxa yes
pten NM008960 yes
Controls
B2M NM009735 beta-2-microglobulin yes
HPRT1 NM013556 Hypoxanthine-guanine phosphoribosyltransferase yes
RPL13A NM009438 60S ribosomal protein L13a yes
GAPDH NM008084 Glyceraldehyde-3-phosphate dehydrogenase yes
ACTB NM007393 beta-actin yes
* data were considered not analyzable by following criteria: more than 1 melting curve peak or/and Cp > 30.
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Figure 5.17: Wild type and EED KO ES cells exhibit differential gene expression. RNA of wild
type (V6.5 and J1) and of EED KO ES cells (E14 and J1) was purified and reverse transcribed to cDNA. Real
time PCR was performed in a 96 well customized PCR array format (SABiosciences, Table 5.2). Shown is
expression relative to HPRT and normalized for V6.5 wild type ES cells by delta delta Cp calculation. Gene
expression of the following categories are shown: A) Pluripotency-, B) Differentiation- and C) Chromatin
modifier-associated genes, D) Other genes.
previous reports, upon ChIP of EED KO ES cells only low amounts of PCR fragments could
be amplified, indicating the absence of the repressive modification at these genomic regions.
In contrast, enrichment of the H3K27me3 modification at the TSS of these genes was detected
in wild type V6.5 and J1 ES cells, as expected.
Western blot and chromatin flow cytometric analyses were performed on the two wild type
and two EED KO ES cell lines to address the question of whether other histone modifications
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Figure 5.18: EED KO ES cells exhibit reduced levels of H3K27me3. Cross-linked and sheared
chromatin of wild type ES cells V6.5 and J1 as well as of EED KO ES cells E14 and J1 was immunoprecipitated
with anti-H3K27me3 or isotype control antibodies. Realtime PCR of the precipitated DNA was done with
primers binding to transcriptional start sites of sox21, bry, hoxa3 and pax5 genes.
besides H3K27me3 were globally affected by EED depletion. As illustrated in Figure 5.19,
ES cells lacking EED showed reduced H3K27me3 and slightly reduced H3K9me3 levels in
comparison to wild type ES cells. Flow cytometry moreover revealed that the acetylation
level of histone H4 at residues K8, 12 and 16 was elevated in EED KO cells while H3K4me3
levels remained unchanged (Figure 5.20).
By these analyses I could show that in EED KO ES cells the levels of the PRC2-catalyzed
H3K27me3 modification were locally and globally depleted. However, the gene expression of
e.g. sox21, whose TSS lacked H3K27me3, was not elevated. Additionally to H3K27me3, which
is directly linked to PRC2, an increase of H4 acetylation levels and a decline of the repres-
sive H3K9me3 modification were also observed. This indicates the existence of a crosstalk
and close interdependence of histone modifying protein complexes as previously observed
[169, 170, 171].
5.4.2 Global nuclear chromatin organization
While the effect of EED on local chromatin organization and histone modifications was well
established in the last decade [131, 172], little is known about its role in the global chro-
matin architecture. Thus, I aimed to deeper analyze the chromatin of EED KO ES cells
by microscopy. First the DNA of undifferentiated ES cell colonies grown on coverslips was
visualized by DAPI staining. Figure 5.21 A shows exemplary colonies of V6.5 wild type
and EED KO E14 ES cells. Heterochromatin regions, which comprise compact chromatin,
and thus can be stained by DAPI, had different characters in wild type and KO ES cells.
DAPI signals in wild type cells were equally distributed throughout the nucleus, forming
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Figure 5.19: Global levels of H3K27me3 and H3K9me3 are reduced in EED KO ES cells. Whole
cell lysates of wild type (V6.5 and J1) and EED KO ES cells (E14 and J1) were prepared. A) In V6.5 and EED
KO E14 lysates EED, EZH2 and for loading control GAPDH were detected by Western blot. The EED-specific
protein band runs below a larger unspecific band. B) H3K27me3, H3K9me3 as well as H3 were detected by
Western blot. C) Relative intensities of H3K9me3 to H3 were obtained by densitometry of Western blot films.
Values were normalized to V6.5 wild type cells. Results are displayed as bar diagram. Average and standard
deviations of 4 experiments are shown.
small clusters that showed fuzzy boundaries. In contrast, in EED KO ES cells DAPI-stained
areas appeared in larger and more defined clusters. An immunofluorescence analysis of the
heterochromatin-associated H3K9 trimethylation affirmed that this modification was enriched
in the DAPIpositive foci of both wild type and EED KO ES cells (Figure 5.21 B). Subsequently,
the number of heterochromatin foci was counted per nucleus. Figure 5.21 C shows the dis-
tribution of heterochromatin foci as a histogram. While wild type ES cells exhibited a wide
range of nuclei with varying numbers of heterochromatin foci, EED KO ES cells had a smaller
variability and fewer heterochromatin foci. Figure 5.21 D gives the corresponding statistical
analysis and demonstrates that the average number of heterochromatin foci in wild type ES
cell nuclei is significantly higher than in EED KO ES cells. Simultaneously the mean area of
single foci was quantified. The results are summarized in Figure 5.21 E. The average size of
individual heterochromatin regions in EED KO ES cell nuclei was significantly larger than in
wild type cells.
As cells show distinct grades of chromatin compaction during different phases of the cell cy-
cle, the altered heterochromatin organization in EED KO ES cells could be the result of a
cell cycle arrest. To analyze whether this is the case, DNA content was analyzed by flow
cytometry in wild type and EED KO ES cells. Figure 5.21 F summarizes cell cycle profiles
and gives percentages of cells in G1, S and G2 phase. Wild type cells comprised more cells in
S phase (48.8% wt versus 31.1% EED KO), while EED KO ES cells contained more cells in
G1 and G2. However, EED KO ES cells were not arrested in cell cycle, but showed a typical
cell cycle profile for ES cells. Hence, the observed heterochromatin foci were presumably not
the result of cell cycle-dependent DNA condensation.
These analyses show that the loss of EED led to an altered nuclear chromatin assembly,
reflected by less and larger heterochromatin foci. However, as reduced global levels of the
heterochromatin-associated H3K9me3 were observed in EED KO ES cells, this indicates that
not more heterochromatin is established in EED KO cells but rather that chromatin is reor-
ganized.
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Figure 5.20: Global levels of H4 acetylation are increased in EED KO ES cells. Wild type (V6.5
and J1) and EED KO ES cells (E14 and J1) were subjected to chromatin flow cytometry using protocol
A (see Material and Methods) and antibodies specific for H3, H3K27me3, H3K4me3, H4K8ac, H4K12ac and
H4K16ac. Mean fluorescence values were normalized to V6.5 wild type levels. Average and standard deviations
of 3 individual experiments are shown.
It was previously reported that ES cell chromatin shows a high degree of plasticity and is
less compacted than the chromatin of committed cells to allow differentiation pathways into
various directions [104]. As the observed heterochromatin structure of EED KO ES cells was
more similar to differentiated cells the EED KO chromatin phenotype was further analyzed
with respect to its dynamics. To this end, V6.5 wild type and EED KO E14 ES cells were
transiently transfected by electroporation with a construct that contains the linker histone
H1 fused to GFP. Transfected cells were subjected to FRAP analyses. The time required for
fluorescence recovery after photobleaching was measured in individual ES cells. Analyses are
summarized in Figure 5.21 G. The data show that fluorescence recovery of H1-GFP in V6.5
ES cells is faster than in EED KO ES cells. The time needed for 50% of total recovery was
more in EED KO ES cells. However, both wild type and EED KO ES cells showed recovery
rates of about 100%, indicating large proportions of mobile chromatin fractions. This result
suggests that due to EED deletion not the proportion of the immobile fraction was increased.
In contrast, differentiated cells were shown to have immobile chromatin fractions, resulting
in incomplete FRAP recovery rates [104].
Together, heterochromatin foci in EED KO ES cells appeared more defined and distinct as
compared to wild type cells, and the chromatin mobility was delayed. These characteristics
are similar to but not completely matching properties of differentiated cells, indicating an
intermediate state of EED ES cells between pluripotent and differentiated cells.
5.4.3 Differentiation potential of EED KO ES cells
To assess the functional consequences of EED deletion I next aimed to analyze the in vitro
differentiation capability of EED KO ES cells. The morphology of either wild type or EED KO
ES cell cultures was similar and indistinguishable (Figure 5.22 A). However, if cultures reached
a critical level of confluence, wild type ES cells usually showed first signs of differentiation
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Figure 5.21: Wild type and EED KO ES cells show different nuclear chromatin organization and
dynamics. Wild type V6.5 and EED KO E14 ES cell colonies were fluorescently stained with A) DAPI and B)
with primary anti-H3K9me3 and secondary anti-rabbit-Cy2 antibodies. C) DAPIpositive heterochromatin foci
were enumerated by ImageJ software analyses. Displayed is a histogram giving the numbers of heterochromatin
foci and the corresponding number of cell nuclei (nwt = 95, nKO = 97). D) Box plot (shown are maximum,
3rd quantile, median, 1st quantile, minimum) summarizing the number of heterochromatin foci per nucleus
in V6.5 wild type and in EED KO E14 ES cells (p < 0.001) E) Box plot summarizing the size (i.e. area)
per heterochromatin focus in arbitrary units. (p < 0.001). F) DNA of V6.5 wild type and EED KO E14 ES
cells was flow cytometrically stained with propidium iodide. G1, S and G2 cell cycle phase distribution was
calculated. (n=2) G) V6.5 wild type and EED KO E14 ES cells were transiently transfected with a transgenic
vector containing H1-GFP. One day post transfection cells were subjected to FRAP analysis. Equally sized
regions were bleached with equal laser settings and fluorescence was measured before and until 45 s after
bleaching. Initial fluorescence intensity was normalized to 1 ((nwt = 8, nKO = 12)).
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with flattened and frayed colony boundaries, while these features were not observed in EED
KO ES cell cultures (data not shown). By applying the ’beating body’ differentiation assay,
the morphology of EBs in suspension and upon transfer to adherent culture conditions were
compared, as displayed in Figure 5.22 A. After clustering in HDs (day 2), EED KO E14
ES cells formed EBs of comparable size to wild type ES cells. But in the subsequent days
of differentiation EED KO cells failed to proliferate and were hardly able to spread on the
TC dish surface as attached EBs. Further, the contracting properties of EBs derived from
wild type and EED KO ES cells were quantified (Figure 5.22 B). The two wild type cell
lines exhibited different efficiencies and dynamics of ’beating body’ formation. While 100%
of J1 EBs were contracting at day 8 of differentiation, a maximum of 30% of V6.5 EBs were
contracting at day 14 of differentiation. In contrast, no ’beating bodies’ could be detected in
EED KO ES cell-derived cultures even after a total differentiation period of 23 days.
ES cells and cells differentiated for 3 and 7 days were then subjected to a colony formation
Figure 5.22: EED KO ES cells have impaired differentiation properties. Wild type V6.5 and EED
KO E14 ES cells were differentiated as HD EBs and allowed to attach to gelatin-coated TC plastic at day 5 for
the formation of contracting ’beating bodies’. A) Light microscopic photographs of wild type and EED KO
ES cells (d0) and of EBs (d2, 5, 6 and 7). B) Displayed are the days of differentiation with the corresponding
percentage of microscopically examined wells which contained contracting EBs. C) An AP colony formation
assay was applied to wild type and EED KO ES cells (d0) as well as to 3- and 7-day old EB cells. Colonies
were counted after 4 days of culture and subsequent staining for AP activity.
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assay, to test whether their self renewal potential was reduced upon differentiation. As shown
in Figure 5.22 C the colony formation capacity of wild type and EED KO ES cells was
similar. But while wild type cells showed progressively decreasing numbers of CFCs during
differentiation, EED KO cells retained a considerable proportion of CFCs even after 7 days
of culture without LIF and feeder cells.
From these data I conclude that the differentiation of ES cells without EED is severely affected,
with an inability to differentiate into functional cardiomyocytes in vitro and with a particular
resistance to differentiation-induced loss of self renewal capacity.
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In the course of this thesis, I analyzed undifferentiated and differentiating stem cells with
respect to gene expression, chromatin state and differentiation potential. Therefore protocols
for the assessment of global histone modification levels in individual cells by flow cytometry
were successfully established and applied to differentiating ES cell cultures, to BM cells and
to EED KO ES cells. The data provide evidence that upon HDAC inhibitor treatment of BM
cells the frequency of cells with in vitro and in vivo hematopoietic activity was augmented
due to selective survival. Further, the results show that ES cells lost functional pluripotent
character after 2 days of differentiation, while the silencing of pluripotency marker expres-
sion was delayed. The utilized differentiation protocol was shown to be determinant for the
progression of differentiation. After 3 days of differentiation ES cells failed to re-activate
Oct4-eGFP transgene expression when placed into ES cell culture conditions, indicating the
loss of pluripotency. Finally, the analyses of ES cells lacking the PRC2 core subunit EED
revealed a reorganization of heterochromatin with delayed chromatin mobility and severe dif-
ferentiation deficits.
The following paragraphs discuss the results on histone acetylation, on emerging cellular het-
erogeneity during ES cell differentiation, on the role of EED in ES cells and on the end of
pluripotency.
6.1 Histone acetylation and HDAC inhibition in stem cells and
committed cell types
Parts of my work comprised the analysis of histone acetylation in hematopoietic and em-
bryonic stem cells and their differentiated derivatives. Generally the acetylation of histones
entails the expression of genes located in proximity [173].
By the optimization of flow cytometric protocols for intranuclear antigen detection I was able
to analyze global histone modification levels (Figure 5.1, 5.2 and 5.3). This method can un-
cover distinct levels of modifications within heterogenous cell populations which is virtually
not possible by Western blot. Though restricted to the detection of global modification levels
without giving values for single gene loci like in ChIP approaches [174], the methodology has
the potential to distinguish between subpopulations because of the advantageous multipara-
metric and graded analysis. Applying chromatin flow cytometry emerging subpopulations,
which differed in global H3K9 acetylation levels, could be detected in differentiating ES cell
cultures. SSEA1positive cells (assumed to be undifferentiated cells) exhibited high global levels
of H3K9ac, while SSEA1negative cells (assumed to be differentiated cells) showed lower levels
(Figure 5.3). However, as indicated by the asymmetric histogram curve, not all SSEA1negative
cells had comparably low global H3K9 acetylation levels. Cells with high H3K9ac and low
SSEA1 levels might represent an additional transient subpopulation. Various reports describe
changes of histone acetylation upon ES cell differentiation. McCool et al. observed augmented
H4 acetylation in 4-day differentiated CCE murine ES cells [175], Golob et al. found increased
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levels of H3K9ac in day 4 EBs of R1 mouse ES cells [103], whereas Lee et al. report strongly
reduced levels of H3K9ac and pan-acH4 in differentiated CCE ES cells [106].
Even though the hyperdynamic state of ES cell chromatin is well established in the field [104],
there are not only controversial results on histone acetylation but also on the overall transcrip-
tional activity in ES cells as compared to their differentiated progeny. Elfroni et al. report
high total mRNA levels in ES cells, while Sampath et al. find increased transcription and
translation activity in EB cells as compared to undifferentiated ES cells [102, 176].
Interestingly, analyzing adult hematopoietic stem cells, no differences of global H4 acetylation
levels in immature Lin− versus committed Lin+ BM cells were observed here, even though
HDAC activity was higher in Lin− than in Lin+ cells (Figure 5.4 and 5.5). Based on the
balanced equilibrium between histone acetylation and deacetylation, one could speculate that
the opposing enzymatic activity of HATs, which could not successfully be analyzed here, is
likewise increased yielding similar net global acetylation levels. High activity and metabolic
rates of chromatin modifying enzymes might reflect the specific plasticity of chromatin states
that enables stem cells to immediately react to intrinsic and extrinsic signals, e.g. by modify-
ing crucial molecular players in order to switch the cell’s chromatin and transcription. High
levels of HDAC activity in Lin− cells could further explain why immature cells selectively
survived the HDAC inhibitor treatment, while mature Lin+ cells became apoptotic (Figure
5.6). If more HDAC activity than necessary is present in Lin− cells, HDAC inhibition will
not immediately be detrimental for the cells’ survival. Indeed, it could not be shown whether
the elevation of histone acetylation or the selective survival of undifferentiated cells or both
of it explain the relative enrichment of progenitor cells upon TSA treatment.
Similarly, in HDAC inhibitor-treated differentiated ES cell cultures I observed that Oct4-
eGFPmedium/high cells selectively survived while Oct4-eGFPlow cells died (Figure 5.15 and
5.16). The assessment of HDAC as well as of HAT activities in Oct4-eGFPhigh and Oct4-
eGFPlow cells or in SSEA1positive and SSEA1negative cells could further elucidate whether
global histone acetylation in adult and embryonic stem cells is regulated in a similar fashion.
However, treatment of murine ES cells with TSA was reported to induce a differentiated mor-
phology of ES cell colonies and to elevate expression of differentiation-associated genes while
expression of pluripotency markers was reduced [175, 177]. In contrast, Ware et al. showed
that the inhibition of HDACs by TSA and sodium butyrate in human and mouse ES cells
increases their self renewal potential [178].
The global inhibition of HDACs is a harsh intervention in the global chromatin architecture.
Despite their similarity in inhibiting HDACs, different small molecules have distinct dose-
dependent side effects, including the induction of apoptosis. Different cell types can respond
differently to HDAC inhibition: MEFs transduced with Oct4, Sox2, Klf4 and c-Myc are more
effectively reprogrammed to iPS cells, while U937 leukemic cells undergo apoptosis and hu-
man cord blood-derived CD34+ cells increase in numbers ex vivo [68, 98, 100].
In summary, high global levels of histone acetylation are not a general prerequisite of undif-
ferentiated stem cells. Presumably, the sum of local histone acetylation marks at regulatory
sites of particular genes are more important indicators for cellular identities.
6.2 Cellular heterogeneity in differentiating ES cell cultures
Even though mouse ES cell lines are of clonal origin and individual cells of one line are ge-
netically identical, there is pronounced variation within cultures of a given cell line. Even
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within one ES cell colony cells differ. This is not only the result of the cell’s position within
an individual colony, i.e. central or rather marginal [179], or the cell cycle stage. Recently
it became obvious that mouse ES cell cultures are heterogeneous for the expression of genes
like SSEA1, Stella, Rex1 and Nanog. Levels of these proteins fluctuate between low and high
levels [32, 33, 34, 35, 36]. This fluctuation is likely to be the result of ES cells differentiating
to epiblast-like cells and vice versa [36].
Assessing SSEA1 levels in undifferentiated ES cells it could be shown here that the cultures
comprised cells with high and medium SSEA1 surface expression (Figure 5.8). Unexpectedly,
the degree of SSEA1-heterogeneity was reduced after 1 day of EB differentiation. Under these
conditions the percentage of SSEA1high cells was elevated about 2-fold from 35% to 75%. I
also observed increased frequencies of Oct4-eGFPhigh cells after 1 day of HD EB differentia-
tion (86% to 92%, Figure 5.11). Hence, this phenomenon could be explained in part by either
residual feeder cells in undifferentiated samples or by an activating effect of the fresh medium
on pluripotency marker expression. However, in case of SSEA1 the apparent shift towards
more cells with high levels of SSEA1 must be the result of enhanced expression of SSEA1 on
the surface of cells that had formerly medium levels of SSEA1. Otherwise more than 50% of
cells (i.e. SSEA1medium ES cells) must have died within 1 day, which could not be affirmed
by the analysis of cell numbers (Figure 5.7). Therefore I hypothesize that the aggregation of
ES cells to an EB in the first days of differentiation provides a microenvironment similar to
ES cell culture conditions, that promotes and maintains pluripotency markers. Additionally,
Oct4, Sox2, Nanog and Rex1 gene expression was elevated at day 1 of differentiation (Fig-
ure 5.9). Interestingly, functional parameters characterizing pluripotency were remarkably
reduced after 1 and 2 days of differentiation (Figure 5.10), indicating that the presence of
putative pluripotency markers (SSEA1, Oct4-eGFP or Nanog, Rex1, Sox2) is not stringently
linked to a cell’s function. Notably, the same cells were subjected both to functional and
expression-based analyses, thus excluding potential variations in differentiation progression
between individual experiments.
Next, by analyzing Oct4-eGFP levels of OG2 cells the impact of distinct differentiation meth-
ods on the loss of pluripotency was demonstrated, monitored by the loss of Oct4-eGFP. It
became apparent that the HD EB differentiation method, which was also used for the exper-
iments discussed above, resulted in a considerable heterogeneity with respect to Oct4-eGFP
levels (Figure 5.11). Thus, both gene expression and functional analyses were performed with
a heterogeneous mixture of cells at distinct states of differentiation. Further, cells which after
7 days of differentiation were still positive for Oct4-eGFP resided particularly in the cen-
tral parts of EBs (Figure 5.12). In contrast, EBs formed by clonal proliferation in semisolid
medium, that avoids the random movement and mutual clustering of single cells, homoge-
neously lost Oct4-eGFP. These cultures contained no Oct4-eGFPpositive cells after 7 days of
differentiation. This strong and steady differentiation progression can be the consequence of
a lack of nutritions because EBs in MC are not supplied with fresh medium, while HD EBs
received fresh medium 2 days after differentiation initiation. Alternatively, as ES cells are
kept separated in MC cultures this might favor fast differentiation in the absence of LIF. To
test for the latter possibility I applied an alternative differentiation method with OG2 ES
cells: ML cultures were seeded with either low or high cell densities. Consistently, uniform
and homogeneous differentiation was observed when started with few cells. The degree of
heterogeneity was higher in ML cultures with high cell densities (Figure 5.13 and 5.14).
Together, these results suggest the existence of an in vitro environment with soluble factors
that act auto-/paracrinely potentially including cell-cell contacts. These conditions can par-
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tially maintain pluripotency marker expression even in the absence of LIF. Indeed, Davey
et al. showed that besides the exogenous LIF growth factor which is withdrawn to initiate
differentiation another ligand for the LIF receptor gp130 exists in ES cell cultures, which is
secreted by ES cells [179, 180]. Thus, especially differentiating ES cells in the inner parts of
EBs have 3 dimensionally contact to other ES cells. Cells are therefore highly exposed to se-
creted extracellular matrix. In addition to soluble factors and their receptors, also the mutual
contacts between cell-adhesion molecules of neighboring cells could sustain the expression of
pluripotency markers. Recently, the expression of E-cadherin and the E-cadherin-mediated
cell-cell contact was reported to be beneficial if not essential for reprogramming of MEFs to
iPS cells [181, 182, 183]. In addition, it was described that adhesion molecules like CD9 and
Pecam1 are down-regulated in differentiating ES cells suggesting their importance for the
undifferentiated state [184]. One might speculate, that the lack of cell-cell communication of
differentiating ES cells hindered to mutual adhesion by either semisolid medium or low cel-
lular density on TC plastic surface, accelerates the loss of pluripotency. Further analyses in
the course of B. Jakob’s Master thesis in our lab underlined this idea as the colony formation
capacity declined faster in low density ML than in HD EB differentiation cultures [185].
Additionally, not only epigenetic regulation but also genetic changes might lead to hetero-
geneity in ES cells or their differentiation daughter cells. Ensenat-Waser et al. notice residual
Oct4-eGFPpositive cells in differentiated ES cell cultures. The cells were resistant to in vitro
differentiation due to a recurrent gain of chromosomes 8 and 9 [186]. However, as the authors
used an unrelated cell line and as I could show an almost complete Oct4-eGFP loss upon
differentiation, I assume that the heterogeneity observed here was due to cell-cell proximity
effects than to alterations of the karyotype.
Finally, focusing on undifferentiated ES cells, it became clear that not every single ES cell
exhibited in vitro pluripotency-associated functions: for example only 40 out of 100 V6.5 ES
cells formed ES cell colonies and only 60 of 1,000 V6.5 ES cells formed EBs (Figure 5.10).
This reflects a functional heterogeneity in undifferentiated ES cell cultures which probably is
the result of heterogeneous cell states.
Altogether, cellular heterogeneity is characteristic for ES cell cultures and it is based on
epigenetically mediated fluctuation of gene expression. Upon differentiation the degree of
heterogeneity increases especially if cells remain in contact. For directed differentiation ap-
proaches (e.g. towards neural cells) this finding might help to establish protocols that give
rise to homogeneously differentiated cells, with low numbers of teratoma-forming ES-like cells.
Alternatively, the application of a differentiation protocol which leads to considerable hetero-
geneity could be used to obtain rare cell types that need the support by other cell types. In
the end, it is beneficial for all research on ES cell differentiation to consider differentiation
conditions.
6.3 Role of PRC2 in ES cell chromatin and function
To maintain pluripotency ES cells must conduct a defined molecular program that upon cell
division enables the heritage of self renewal and differentiation potential. Therefore genes
which are responsible for differentiation must be efficiently repressed without permanent si-
lencing to allow for future expression. The PRC2 is essential for H3K27 trimethylation which
serves as a reversible, repressive modification [131]. In ES cells lacking EED other core
subunits of PRC2 are depleted on the protein level while their RNA remains transcribed
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[131, 187]. Consequently, H3K27 methylation is almost absent in EED KO ES cells and the
expression of PRC2 target genes was reported to be elevated [188].
In the scope of this thesis I confirmed that EED RNA and protein were depleted in EED KO
ES cells (Figure 5.17 and 5.19) and that the HMT EZH2 was expressed on RNA level while
EZH2 protein could not be detected (Figure 5.17 and 5.19). In parallel, H3K27 trimethyla-
tion levels were strongly reduced (Figure 5.18, 5.19 and 5.20). Despite the local absence of
the repressive H3K27me3 mark at the transcriptional start sites of bivalently regulated genes
like Sox21 or Bry, no derepression of these genes was observed, which is contradictory to the
existing literature (Figure 5.17 and 5.18) [120, 119]. It can be speculated that in other studies
different cell lines were used and that not all known bivalent genes show elevated transcrip-
tion upon PRC2 depletion. Perhaps other repressive epigenetic mechanisms compensate the
loss of PRC2. Alternatively, different culture conditions (media, feeders) or passage numbers
influence the cells’ transcriptome. EED KO ES cells like their wild type counterparts grew
as morphologically undifferentiated colonies with typical ES cell morphology and AP activity
(Figure 5.22). In contrast to some reports I did not observe a flattened colony morphology
commensurate to differentiated cells [119]. The expression levels of pluripotency genes were
similar to wild type cells or even elevated and the colony formation capacity was unaffected by
EED KO (Figure 5.17 and 5.22). Wild type and EED KO ES cells proliferated at comparable
levels and exhibited similar cell cycle distributions (Figure 5.21). These observations indi-
cate that EED KO ES cells can be expanded and cultured in an undifferentiated pluripotent
state. This is further supported by the fact that EED KO ES cells can be maintained under
groundstate pluripotency culture conditions in the presence of MEK and GSK3 inhibitors [37]
(preliminary data). It was earlier shown by Chamberlain et al. that ES cells without EED
can contribute to chimeric mice up until embryonic day 12.5 [150]. Even though the authors
claim that due to this finding EED is dispensable for pluripotency, this was not proven. The
generation of life-birth following complementation of tetraploid blastocysts, the most strin-
gent test for pluripotency, was not performed [42]. A recent report by Pereira et al. describes
the requirement of EED for successful reprogramming of B cells following cell fusion [148].
Along these lines, it was shown that the transcription of EED is directly controlled by STAT3
and Oct4 in ES cells [147]. These findings indicate EED’s important role for maintenance of
the molecular pluripotency program in ES cells.
Though EED KO ES cells if cultured under ES cell conditions in the presence of LIF show
typical characteristics of pluripotent cells, they have deficits in differentiation. This is re-
flected by the inability to give rise to alive offspring upon blastocyst injection, the inability
of forming contracting cardiomyocytes in vitro and the persisting colony forming cells after
7 days of in vitro differentiation [150] (Figure 5.22). While the effect of EED deletion on the
state of pluripotency seems mild, differentiation is compromised. Thus, EED KO ES cells
exhibit problems to exit the pluripotent groundstate. Therefore, I hypothesize that PRC2
is not only involved in the repression of developmental genes in ES cells but EED is also
essential for the silencing of genes during differentiation. It is known that e.g. the Oct4 pro-
moter becomes H3K27 trimethylated during differentiation [146]. Oct4 gene expression must
be silenced via alternative mechanisms in EED KO ES cells.
Besides the consequences of EED deletion on gene expression and cellular function, also the
global chromatin in EED KO ES cells was analyzed. So far little is known about the role
of PRC2 on the global nuclear organization of chromatin. Global levels of acetylated his-
tones were increased (Figure 5.20). As it is known that HDACs, which remove acetyl groups
from core histones, are assembled with the PRC2 in ES cells, this result is not unexpected
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because of the complex’s instability upon EED deletion [141]. Interestingly, besides the PRC2-
mediated repressive H3K27me3 mark, another repressive mark, H3K9me3, was also reduced
in EED KO ES cells, even though to a lesser extent (Figure 5.19). Earlier it was observed
that PRC2 and the methylation activity of H3K9 are linked and that EED can directly bind
to H3K9me3 [138, 139, 140, 132]. However, enzymes that directly methylate H3K9 are not
part of the PRC2 core complex. It remains open whether in EED KO ES cells the activity
of one or more of the 5 known H3K9 HMT is reduced or whether activities of KDMs are
affected [189, 190]. As EED binds H3K9me3 with high affinity [132], it is possible that in KO
ES cells the lack of this particular binding leads to reduced global levels of H3K9me3. In ES
cells the PRC2 might assemble with H3K9 HMTs and also an enhancement of the enzymatic
activation of H3K9 HMTs upon EED-H3K9me3 binding is conceivable. Further it must be
assessed which genomic regions are affected by the apparent global H3K9me3 decrease. This
can be done e.g. by applying genome-wide ChIP technologies.
In parallel to decreased H3K9me3 levels, the nuclear distribution of H3K9me3-enriched chro-
matin was changed in EED KO ES cells (Figure 5.21). Less foci of bigger size and with
well-defined borders were found in EED KO as compared to wild type ES cells. This nuclear
architecture reminds of differentiated cell types with respect to the high-defined distinction
between eu- and heterochromatin regions. However, Meshorer et al. reported that the number
of heterochromatin spots increased while their size decreased during the differentiation of ES
cells to NSCs [104]. It is worth investigating whether other differentiated cell types besides
NSCs also exhibit more and smaller heterochromatin foci or whether this appearance is spe-
cific for NSCs. It was speculated that by changing nuclear organization from poorly defined
and diffusely distributed heterochromatin to distinct clusters, the gene expression repertoire
and developmental potential of cells becomes restricted [104]. In case of EED KO ES cells this
is only partially true, because most features of pluripotent cells (including gene expression of
pluripotency markers) are preserved whereas the differentiation potential is disturbed. Thus,
EED KO ES cells are inflexible concerning their developmental possibilities which might be
reflected by well-defined and distinct chromatin domains. FRAP analyses revealed that EED
KO like wild type ES cells contained similarly large proportions of mobile linker histone chro-
matin fractions (Figure 5.21). In contrast to differentiated cell types which were reported to
have increased immobile chromatin fractions [104], EED KO ES cells recovered fluorescence
fully. However, the halftime of recovery was reduced, indicating that chromatin mobility in
general is retained, but slowed down.
In summary, EED KO ES cells exhibit typical properties of pluripotent cells, but appear to be
restricted to the undifferentiated state. EED KO ES cells have difficulties to exit pluripotency
upon differentiation induction - they could be described as ’trapped in the pluripotent state’.
6.4 The end of pluripotency
In the course of this thesis, I performed analyses to better define the loss and end of pluripo-
tency. Applying an in vitro differentiation approach for ES cells using the HD method to form
EBs I was able to show that functional properties delineating pluripotency, like self renewal
and differentiation capacity, were immediately and strongly reduced in early differentiated
ES cell cultures (Figure 5.10). This is surprising if one considers that in these early stages
pluripotency genes remained highly expressed and SSEA1 levels changed only marginally or
not at all (Figure 5.8 and 5.9). Most of the analyzed pluripotency-associated transcription
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factors (Oct4, Rex1, Sox2, Nanog) or surface markers (SSEA1) were increased after 1 day
of LIF withdrawal. A potential contamination with residual feeder cells in undifferentiated
ES cell samples leading to lower pluripotency marker levels in day 0 as compared to 1-day
differentiated samples, seems unlikely because functionally pluripotent cells with e.g. colony
formation capacity were most frequent in undifferentiated ES cell samples. The assays per-
formed here to test for pluripotency were not as stringent as teratoma formation, generation
of chimeras with germline contribution or the complementation of tetraploid blastocysts,
but they were able to mirror pluripotency levels (Figure 5.10). From these observations it
can be concluded that ES cells after short-term differentiation of only 1 to 2 days show a
functional loss of pluripotency before this is designated by declining levels of pluripotency
markers. Similar results were described previously [191]. It is, however, conceivable that
RNA of pluripotency-associated genes was synthesized and hence, is detectable, but RNA is
not translated into protein. An alternative scenario is that pluripotency-associated proteins
are present and hence traceable, but no longer produced. Therefore, I hypothesize that in
very early stages of ES cell differentiation functional pluripotency loss is based on immedi-
ate molecular switches, e.g. post-translational modifications, that alter protein functions and
subsequently cellular identities.
The progression of differentiation and thus the loss of pluripotency is also dependent on the
method by which ES cells are differentiated. By detecting Oct4-eGFP levels I found that
differentiation in MC or as ML at low cellular densities yielded the fastest and most uniform
differentiation progression (Figure 5.11 and 5.13). Palmqvist et al. reported that the capacity
of R1 ES cells to give rise to chimeric mice upon injection into blastocysts declines from 100%
to about 20% within 24 h and to almost 0% after 48 h of differentiation [191]. In the same
study ES cells were differentiated attached to culture dishes in the absence of LIF. Other dif-
ferentiation methods, e.g. aggregation of ES cells to EBs, might give other outcomes, because
the degree of cellular heterogeneity is higher in aggregation EBs than in ML cultures. For the
generation of chimeric animals randomly 5-15 cells are injected into blastocysts. Hence, cellu-
lar heterogeneity will have an impact on the level and degree of chimera formation. Individual
undifferentiated cells within heterogeneous differentiation cultures would be sufficient to take
part in blastocyst seeding and consequently generate chimeric mice, even though other cells,
maybe the majority, of co-injected cells have features of differentiated cells. Therefore it is
important to know the composition of cell populations of which single cells are injected into
blastocysts. Based on my data, I assume that differentiating ES cells without mutual contact
(i.e. clonal EBs or low cell density ML) stop contributing to chimeric animals at earlier dif-
ferentiation time points, whereas the chimeric outcome of heterogenous differentiated cells is
a stochastic event.
The question of whether the ’end of pluripotency’ is a point of no return or whether a time
window of ambiguity exists which allows a regain of pluripotency, is difficult to approach
directly. Due to the fact that currently no good markers exist that recognize cells in the
process of early commitment, the identification of cells within a potential time window of
ambiguity seems challenging. Generally, developmental processes are unidirectional and one
would not expect de-differentiation without malignant transformation [192] or without exter-
nal manipulation, like the induction of pluripotency by ectopic expression of factors like Oct4,
Sox2 and Klf4 in somatic cells [53]. Here Oct4-enhancer driven eGFP in OG2 ES cells was
used to assess whether expression of the pluripotency factor Oct4 can be re-elevated if once
reduced, i.e. whether ES cell culture conditions alone can rescue Oct4-eGFP expression in 3
days differentiated ES cells. The results presented here suggest that if Oct4-eGFP levels fall
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below a threshold, Oct4-eGFP can not be reactivated by culturing cells under ES cell growth
conditions on MEFs (Figure 5.16). Only contaminating Oct4-eGFPhigh cells overgrew the
cultures (Figure 5.15 and 5.16). To deeper unravel the end of pluripotency, earlier differen-
tiated cell types must be subjected to analyses. However, adequate markers for such kind of
analysis have yet to be identified.
Though also pluripotent, EpiSCs represent a cell type distinct from ES cells and exhibit
characteristics of more differentiated cells. EpiSCs are generally incapable of contributing to
chimerism upon blastocyst injection [39]. ES cells can reversibly differentiate to epiblast-like
cells that represent an intermediate cellular entity between ES cells and EpiSCs. ES and
epiblast-like cells are described to be in a dynamic equilibrium [36]. ES cells, epiblast like
cells as well as EpiSCs express Oct4 [36]. However, in contrast to EpiSCs, epiblast-like cells
regulate their gene expression not via DNA methylation but rather via reversible histone
modifications [36]. Therefore, the end of pluripotency is most probably defined by robust
epigenetic marks which guide a cell’s fate beyond a point of no return. Robust epigenetic si-
lencing mechanism are more difficult to revert and include DNA methylation and higher order
compaction by heterochromatin-associated proteins like HP1. This hypothesis is further sup-
ported by the observation that differentiated ES cells lacking Dnmt1, Dnmt3a and Dnmt3b
(triple KO) can reactivate Oct4-eGFP expression after rescue in ES cell culture condition
(unpublished data, communication with D. Meilinger of H. Leonhardt lab). However, appro-
priate culture conditions that supply either LIF or a cocktail of small molecule inhibitors for
LSD1, ALK5, MEK, FGFR, and GSK3 were shown to revert EpiSCs to ES cells, including
the erasure of DNA methylation marks [38, 39].
Finally, I conclude that for studies on the end of pluripotency it is essential (i) to consider the
differentiation method, (ii) to analyze cells on the single cell level rather than in bulk cultures
and (iii) to rely on functional assays instead of marker expression. However, in recent time
there is striking progress in the field of cellular reprogramming with the identification of re-
programming genes that can replace one another (like nuclear receptor Nr5a2 or E-cadherin
replace Oct4 [193, 183]) and small molecules that enhance reprogramming. Thus, the step
to reprogram cells by just applying optimal culture conditions and creating a stimulating
microenvironment appears not out of reach. As culture conditions for the groundstate of
pluripotency exist that support self renewal of pluripotent cells, it is conceivable that somatic
cells if treated with appropriate small molecules can stochastically turn on pluripotency gene
expression. Consequently, these cells would selectively survive and expand. This reflects the
potential that every cell, differentiated or uncommitted, holds in its genetic information. By
deeper understanding of cellular programs and epigenetic regulation, I assume that in future
the ’end of pluripotency’ can be safely reverted without genetic approaches which will open
gateways towards safe regenerative therapies.
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7.1 Material
7.1.1 Mice
Strain Characteristica Source
C57BL6 Ly5.1 wild type, inbred Charles River
C57BL6 Ly5.2 wild type, inbred Charles River
NMRI wild type, outbred Harlan
B6;CBA-Tg(Pou5f-
eGFP)2Mnn/J
eGFP under transgenic Oct4
promoter control
kindly provided by
Prof. Scho¨ler
DR4
C57BL6 with four antibiotic
resistance genes
kindly provided by
Prof. Lu¨bbert
C57BL6J-Thyc−2J C57BL6 albino Charles River
7.1.2 Mouse ES cell lines
Name Genetic background Specific feature Source
V6.5 129/Sv X C57BL6 wild type open biosystems
D3 129/Sv X 129/Sv wild type
OG2 CBA X C57BL6
eGFP under
transgenic Oct4
promoter control
kindly provided by
Prof. Scho¨ler
J1 129/Sv X 129/Sv wild type
kindly provided by Dr.
Wutz, Cambridge UK
EED KO J1 129/Sv X 129/Sv knockout of eed
kindly provided by Dr.
Wutz, Cambridge UK
EED KO E14 129/Sv X 129/Sv knockout of eed
kindly provided by Dr.
Wutz, Cambridge UK
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7.1.3 Cell culture media and supplements
Standard ES cell medium
Ingredient Concentration Volume Distributor
DMEM high glucose 400 ml PAA
FCS, ES cell tested 15% 75 ml PAA
Sodium pyruvate 1 mM 5 ml PAA
Penicillin, Streptomycin 100 U/ml, 0.1 mg/ml 5 ml PAA
L-Glutamine 2 mM 5 ml PAA
Non-essential aminoacids 1x 5 ml PAA
Beta-Mercaptoethanol 0.1 mM
3.5 µl in 5 ml
Hepes
Sigma, PAA
LIF-conditioned medium 500 µl own production
2 inhibitor ES cell medium
Ingredient Concentration Volume Distributor
DMEM F12 Ham 50% 50 ml Invitrogen
Neurobasal 50% 50 ml Invitrogen
N2 0.5% 0.5 ml Invitrogen
B27 1% 1 ml Invitrogen
Glutamax 2 mM 1 ml Invitrogen
Insulin 1 mg/ 100 ml 1 mg Sigma
BSA 2.5 mg/100 ml Sigma
Beta-Mercaptoethanol 0.1 mM
0.7 µl in 1 ml
Hepes
Sigma, PAA
LIF-conditioned medium 100 µl own production
PD0325901 1 µM
10 µl von 10
mM stock
Axon medchem
CHIR 99021 3 µM
30 µl von 10
mM stock
Axon medchem
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Differentiation medium
Ingredient Concentration Volume Distributor
DMEM high glucose 425 ml PAA
FCS 10% 50 ml Biochrome
Sodium pyruvate 1 mM 5 ml PAA
Penicillin, Streptomycin 100 U/ml, 0.1 mg/ml 5 ml PAA
L-Glutamine 2 mM 5 ml PAA
Non essential aminoacids 1x 5 ml PAA
Beta-Mercaptoethanol 0.1 mM
3.5 µl in 5 ml
Hepes
Sigma, PAA
EB formation methylcellulose medium
Ingredient Concentration Volume Distributor
M3120 ES-cult 1x 40 ml
Stem Cell
Technologies
FCS 15% 15 ml Biochrome
L-Glutamine 2 mM 1 ml PAA
mSCF 40 ng/ml 40 µl Peprotech
MTG 150 µM 124 µl Sigma
IMDM 34 ml Invitrogen
MEF medium
Ingredient Concentration Volume Distributor
DMEM low glucose 500 ml PAA
FCS 10% 50 ml Biochrome
Sodium pyruvate 1 mM 5 ml PAA
Penicillin, Streptomycin 100 U/ml, 0.1 mg/ml 5 ml PAA
L-Glutamine 2 mM 5 ml PAA
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BM culture medium
Ingredient Concentration Volume Distributor
IMDM 500 ml Invitrogen
FCS 20% 100 ml Sigma
BSA 0.1%
6.7 ml of
7.5% solution
Invitrogen
Sodium pyruvate 1 mM 5 ml PAA
Penicillin, Streptomycin 100 U/ml, 0.1 mg/ml 5 ml PAA
L-Glutamine 2 mM 5 ml PAA
IL-3 10 ng/ml Peprotech
IL-6 20 ng/ml Peprotech
mSCF 50 ng/ml Peprotech
Hematopoietic methylcellulose medium
Ingredient Concentration Volume Distributor
MethoCult 1x 40 ml
Stem Cell
Technologies
FCS 30% 30 ml Biochrome
Penicillin, Streptomycin 100 U/ml, 0.1 mg/ml 1 ml PAA
L-Glutamine 2 mM 1 ml PAA
BSA 1% Invitrogen
BM culture medium 1/6
500 µl per
2.5 ml
see above
Beta-Mercaptoethanol 0.1 mM
0.7 µl in
1 ml PBS
Sigma, PAA
PWM 2%
Stem Cell
Technologies
IL-3 10 ng/ml Peprotech
IL-6 20 ng/ml Peprotech
mSCF 50 ng/ml Peprotech
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7.1.4 Antibodies
Primary antibodies
Target Species Distributor
H3 rabbit, polyclonal Abcam
H3K4me3 rabbit, polyclonal Abcam
H3K4me3 rabbit, polyclonal Diagenode
H3K9ac rabbit, polyclonal Abcam
H3K9me3 rabbit, polyclonal Upstate
H3K27me3 rabbit, polyclonal Abcam
H3K27me3 rabbit, polyclonal Diagenode
H4 rabbit, polyclonal Upstate
H4K8ac rabbit, polyclonal Upstate
H4K12ac rabbit, polyclonal Upstate
H4K16ac rabbit, polyclonal Upstate
pan acH4 rabbit, polyclonal Upstate
SSEA1 mouse, monoclonal hybridoma bank
c-Kit mouse, monoclonal own production
Sca-1-PE mouse, monoclonal BD
CD4 (-biotin) rat, monoclonal own production
CD8 (-biotin) rat, monoclonal own production
Mac1 (-biotin) rat, monoclonal own production
Gr1 (-biotin) rat, monoclonal own production
Ter119 (-biotin) rat, monoclonal own production
B220 (-biotin) rat, monoclonal own production
Ly5.1 mouse, monoclonal BD
EZH2 rabbit, polyclonal Diagenode
EED rabbit, polyclonal Santa Cruz
GAPDH mouse, monoclonal Santa Cruz
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Secondary antibodies / reagents
Target Label Distributor
mouse Cy2 Dianova
mouse Cy3 Dianova
rabbit PE Dianova
rabbit Cy2 Dianova
biotin (streptavidin) PE-Cy5 BD
biotin (streptavidin) APC Dianova
mouse HRP Amersham
rabbit HRP Amersham
rat goat, micro beads Miltenyi
goat biotin BD
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7.1.5 Primers
All quantitative real time PCRs (either for gene expression or for ChIP analyses) were per-
formed using an annealing temperature of 60◦C. Primers were ordered from Eurofins MWG
Operon.
Gene expression primers
Gene Sequence
Product
size (bp)
beta-actin GATATCGCTGCGCTGGTCGTC 132
ACGCAGCTCATTGTAGAAGGTGTGG
eed GCACAGAGATGAAGTTCTGAGTGCTG 133
ATAAGACTCCTTAATTGCATTCATCATCCT
oct4 CCGTGAAGTTGGAGAAGGTG 194
GAAGCGACAGATGGTGGTCT
nanog TCTTCCTGGTCCCCACAGTTT 100
GCAAGAATAGTTCTCGGGATGAA
sox2 GCGGAGTGGAAACTTTTGTCC 157
CGGGAAGCGTGTACTTATCCTT
rex1 GGC CAG TCC AGA ATA CCA GA 232
GAA CTC GCT TCC AGA ACC TG
bry CAGCCCACCTACTGGCTCTA 123
GAGCCTCGAAAGAACTGAGC
nestin CAG AGA GGC GCT GGA ACA GAG ATT 469
AGA CAT AGG TGG GAT GGG AGT GCT
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ChIP primers
Gene Sequence
Product
size (bp)
oct4 TCCGCCAGCACAGGAATG 95
CAGAGCCTCAGATGGAGATACC
nanog TTCAGATAGGCTGATTTGGTTGG 115
GATCATAGAAAGAAGAGTTAAATGTCTAATGC
klf4 TCGGTCCCTCTCCGCGTTCC 199
TCCCGTAGGGTGGGGGTGAG
irx2 TAACACGGCCTGAAATCTTCTC 198
GCATCCCACTTCTACAGTCCTC
hoxa3 AATTACCTCCCTGCATCTCAAA 165
TTATCAGAGCAGACCCACAATG
pax5 ATGGGAGTTTGTTTTCCTGTGT 174
AGTGATGTTTGGCCTAATCCTG
dlx1 ATGTCTCCTTCTCCCATGTCC 178
ACTGCACGGAACTGATGTAGG
tcf4 CGGATGTGAATGGATTACAATG 184
ATTGTTCTTCGGTCTTGTTGGT
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7.1.6 Buffers and solutions
PBS
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4
FACS-buffer
PBS, 0.3 % BSA, 0.1% NaN3, pH 7.4
Flow FisH buffer
21.4 mM Tris HCl pH 7.1, 21.4 mM NaCl, 80.25% v/v deionized formamide, 1.07% BSA
Protein sample buffer
100 mM Tris HCl pH 6.8, 200 mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol
Trypsin
0.05% trypsin in PBS, commercially purchased from PAA
Gelatin
0.1% in PBS
Gey’s Solution
20% Stock A:
NH4Cl 35.0 g, KCl 1.85 g, Na2HPO4-12·H2O 1.5 g, KH2PO4 0.12 g, Glucose 5.0 g, Phenol
red 50 mg, bring to 1 L
5% Stock B:
MgCl2-6·H20 0.42 g, MgSO4-7·H20 0.14 g, CaCl2 0.34 g, bring to 100 ml
5% Stock C:
NaHCO3 2.25 g, bring to 100 ml
70% water
Western blot stripping solution
100 mM Beta-Mercaptoethanol, 2% SDS, 62.5 mM Tris HCl pH 6.7
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7.1.7 Commercial kits and reagents
Kit / Reagent Distributor
M-MLV Reverse transcriptase kit Invitrogen
rDNase I Ambion
Alkaline Phosphatase kit Sigma
ABsolute SybrGreen Mix Thermofisher
ChIP Kit Upstate
PeqGold RNAPure Peq Lab
RNeasy Mini kit Qiagen
Fixation and Permeabilization buffers eBioscience
AnnexinV-FITC Apoptosis detection kit BD
HDAC activity kit Upstate
Customized PCR gene expression array
(Table 5.2)
SABiosciences
TSA Sigma
VPA Sigma
ATRA Sigma
DAPI Sigma
Hoechst 33343 Sigma
Hoechst 33258 Sigma
Prolong Gold, mounting medium Invitrogen
Mouse embryonic stem cell Nucleofection kit Amaxa
RNase and DNase free water Sigma
Protease inhibitor cocktail Applichem
Nitrocellulose membrane PROTRAN Whatman
Tissue-Tek OCT
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7.1.8 Cell culture plastic, technical devices and software
Cell culture plastic Distributor
2 ml cryotubes PAA
3.5 cm TC plates Greiner
3.5 cm suspension plates Sarstedt
6 cm TC plates PAA
10 cm TC plates Greiner
10 cm petri dish Greiner
15 cm petri dish Sarstedt
75 cm2 TC flasks, red cap Sarstedt
24 well plates TC Nunc
24 well plates, suspension Greiner
48 well plates TC Greiner
15 ml tubes Greiner
50 ml tubes Greiner
flexiPERM chamber Sarstedt
70 µm cell strainer Greiner
Technical device Distributor
Nucleofector I Amaxa / Lonza
Bioruptor Diagenode
FACS Canto I BD
Real time Cycler Rotor Gene 3000 Corbett
Fluorescence microscope DM IRBE Leica
Cell culture microscope EVOS AMG
Spectra Thermo, ELISA reader Tecan
Software Distributor
ImageJ NIH
FlowJo Tree Star, Inc.
FACS Diva BD
Rotor Gene 6 Corbett
Micron EVOS AMG
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7.2 Methods
7.2.1 Mouse cell isolation and transplantation
MEF isolation
MEFs were isolated from E12.5 - E14.5 mouse embryos of wild type mice. Pregnant mothers
were sacrificed and embryos were freed from residual extraembryonic tissue. The heads and
inner organs were removed by using forceps and scalpel. The remaining embryonic tissue was
incubated in trypsin solution over night at 4◦C to allow diffusion of the enzyme inside the
tissue. The enzymatic activity was induced by 30 min incubation at 37◦C and stopped by the
addition of a large volume of MEF medium. The tissue was further disrupted by thorough
pipetting. Large tissue particles were allowed to settle down and the supernatant containing
single MEF suspension was spun down at 200x g and cells were resuspended and plated in
MEF medium at a density of 1/3 embryo per 10 cm TC plate. One or two days later MEFs
were trypsinized and one plate was frozen in three cryotubes, labelled ”passage 0”.
BM isolation
Male C57BL6 Ly5.1 mice at an age of 8 to 12 weeks were sacrificed, femur and tibia bones
were isolated and the BM was flushed out with 0.3% BSA in PBS by using needle and syringe.
Single cell suspension was obtained by thorough pipetting and the pass though a 70 µm cell
strainer. Erythrocytes were depleted by incubation in hypotonic Gey’s solution for 6 min on
ice and the BM cells were subsequently collected in a phase of FCS by centrifugation.
BM transplantation
Freshly isolated or cultured and treated BM cells were injected (20,000 cells per animal)
intravenously into lethally irradiated (11 Gy) female C57BL6 Ly5.2 mice together with 1 ·105
Ly5.2 competitor BM cells. Before transplantation the cultured cells were washed twice with
PBS. After an engraftment period of 16 weeks blood of the transplanted animals was collected
from the tail veins, white blood cells were purified by Ficoll gradient centrifugation and finally
used for flow cytometric analyses.
BM transplantation were performed together with V. Hornich and A.M. Mu¨ller.
7.2.2 Cell culture
All cells were cultured at 37◦C and 5% CO2 in a humidified atmosphere. Cells were frozen
in 10% DMSO in FCS.
BM
Freshly isolated BM cells were cultured for two days in 24 well suspension plates at a density
of 1 · 106 cells per 1 ml BM culture medium accordingly supplemented with TSA or VPA.
MEF
MEFs were either used directly upon isolation or thawed and were used for no more than 6
passages. MEFs were maintained in TC flasks (T75 or T175) with MEF medium and split
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once or twice a week by washing them once with PBS, incubating them with minimum volume
of trypsin at 37◦C for maximal 5 min, washing them out with MEF medium and distributing
them at equal amounts into three new flasks. For mitotic inactivation confluently grown
MEFs were treated with mitomycin C (10 µg/ml) for two to three hours, washed at least
two times with PBS, trypsinized and counted. Inactivated MEFs were plated at a density of
1 · 106 cells per 6 cm TC plate. After some hours or the next day MEFs had attached and
were read as feeder cells for subsequent ES cell culture.
ES cells
Usually, ES cells were thawed and cultured in standard ES cell medium on inactivated MEF
feeders in 6 cm TC plates. Medium was changed every day and cells were passaged at a ratio
of 1/10 every second day. For this, cells were washed twice with 5 ml of PBS and trypsinized
by incubation with 0.5 ml trypsin for 5 min at 37◦C. Trypsin reaction was stopped by the
addition of 5 ml of ES cell medium and cells were dissociated by pipetting. After centrifugation
at 90x g the pellet was resuspended in ES cell medium and 1/10 was given to a new culture
dish onto MEFs in ES cell medium. ES cells cultured in 2 inhibitor medium were grown on
gelatin coated 3.5 cm or 6 cm TC plates and passaging was done by the usage of accutase.
To obtain feeder-free ES cells the heterogenous cell suspension of one 6 cm plate (comprising
ES cells and MEFs) was given to a gelatine coated 10 cm TC plate for 45 min. This allows
MEFs to strongly attach to the bottom of the dish while ES cells only loosely adhere and
dead cells as well as cell clusters remain in suspension. ES cells are isolated by removing the
suspension phase and washing off the loosely adhered ES cell fraction from the fixed MEFs.
ES cell differentiation
For the induction of differentiation, feeder-free ES cells were cultured in the absence of LIF
and MEFs with reduced FCS concentration. This was either achieved by the formation of
EBs or by the growth as a dish-adhered ML. EBs were generated by clustering 1,000 ES cells
in 30 µl differentiation medium as HDs at the lids of 15 cm petri dished in the presence of
PBS for humidification. After two days the formed EBs from one 15 cm lid (usually 120 EBs)
were transferred into 10 cm petri dishes in 10 ml of fresh differentiation medium and cultured
for up to 7 days. For further analyses EBs were dissociated by harvesting free floating EBs,
allowing them to settle down by gravity, washing them twice in PBS and incubating them for
5 to 10 min at 37◦C in trypsin. By the addition of medium, thorough pipetting and the help
of a 70 µm cell strainer single cell suspensions could be made.
ML differentiation was performed by plating feeder-free ES cells in differentiation medium on
10 cm TC plates at appropriate density. Cells were harvested by trypsination as explained
above.
Differentiation towards clonal-derived EBs in MC medium was done as explained below for
the EB formation assay. For harvesting MC-derived EBs the semisolid medium was diluted
by warm PBS, EBs were washed out of the dish and subsequently dissociated to single cells
with trypsin.
’Beating body’ assay
For the differentiation of ES cells towards spontaneously contracting cardiomyogenic cells,
first EBs were generated in HDs for two days as explained above. The EBs were transferred
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to petri dishes for three more days and finally individual EBs were moved into gelatin coated
wells of 48 well TC plates. From then on the differentiation medium was changed every day
and EBs were subjected to an everyday microscopic observation to identify contractions.
EB formation assay
To analyze the potential of cells to form EBs, 1,000 feeder-free ES cells or differentiated cells
were plated in 1 ml EB formation MC medium into 3.5 cm petri dishes. In this semisolid
medium the formation of EBs is the result of clonal proliferation and not of aggregation. One
week after plating the number of EBs was enumerated by light microscopy.
Colony formation assay for ES cells
To analyze the potential of cells to form colonies, defined numbers of feeder-free ES cells or
differentiated cells were transferred onto a MEF feeder layer in standard ES cell medium. After
four days the colonies were fixed and the activity of their AP was visualized by applying the
Alkaline Phosphatase Kit according to manufacturer (see Material). Only APpositive colonies
were enumerated by light microscopy.
Colony formation assay for HPCs
Freshly isolated or 2-day cultured BM cells were plated at densities between 1,000 and 5,000
cells per 1 ml hematopoietic MC medium as triplicates in 3.5 cm suspension culture plates.
After 10 days all colonies consisting of at least 50 single cells were enumerated. For the
secondary colony formation, colonies were washed out of the dish with warm PBS , cells were
counted and plated again under the same conditions as before. After 10 days frequencies of
secondary colonies were determined.
7.2.3 Molecular biology
RNA isolation
Total RNA of cells was purified by using peqGOLD RNA Pure, an optimized guanidine
isothiocyanate/phenol reagent for RNA extraction, or by the Qiagen spin column RNeasy Mini
Kit. RNA isolation was performed as recommended by the manufacturer. The concentration
and purity was measured photospectrometrically.
cDNA synthesis
Purified RNA was reverse transcribed by the M-MLV reverse transcriptase. Briefly, 1 µg of
total RNA were used and first remaining genomic DNA was digested for 30 min at 37◦C
by DNase. The reaction was stopped by the addition of 7% v/v 25 mM EDTA and by 10
min heat inactivation at 65◦C. Oligo dT primers (5’ TTT TTT TTT TTT TTT T 3’) were
allowed to anneal to poly A RNA for 5 min at 65◦C followed by rapid chill down on ice.
Together with 5 mM dNTPs and reverse transcriptase as well as with buffers (provided by
the manufacturer, see Material) cDNA was synthesized for 1 h at 37◦C. Usually cDNA was
further diluted with RNase and DNase free water before subsequent PCR.
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ChIP
ChIP was done by applying a ChIP kit (see Materials), individual steps were performed as
recommended by the manufacturer and a protease inhibitor cocktail was added to all solu-
tions.
For ChIP, chromatin of 1·106 cells was cross-linked to DNA for 10 min at 37◦C by 1% formalde-
hyde in medium. Next, cells were washed twice in ice cold PBS and subsequently resuspended
in 200 µl SDS lysis buffer. DNA was sheared in the Bioruptor at 4◦C in 60 cycles with one
cycle comprising 30 s of sonication and 30 s of no sonication. One percent was used as input
material and the remaining chromatin was split equally to H3K27me3 and isotype control
precipitation. Following over night incubation with 5 µl of antibody (H3K27me3 or isotype
control) DNA was isolated by phenol chloroform and ethanol precipitation. DNA of IPs and
input was dissolved in 30 and 100 µl water, respectively, and used for real time PCR.
ChIP analyses were performed together with M. Becker.
Quantitative realtime PCR
Realtime PCRs were performed with cDNA and ChIP-DNA.
For gene expression analyses generally 1 µl cDNA was mixed with 10 µl 2x SybrGreen Mix,
8.5 µl water and each 0.25 µl of 100 pM primers. Analyses were referred to beta-actin by
the delta-delta Ct calculation. However, Ct values for beta-actin were tried to be aligned for
comparative samples. All reactions were carried out as duplicates in the Corbett Rotor Gene
RG 3000 real time cycler with the following PCR program: 95◦C 15 min, 40x (95◦C 10 s,
60◦C 20 s, 72◦C 30 s, 80◦C 20 s), 50◦C 1 min, 67◦C to 95◦C with 0.5◦C temperature increase
per 5 s. Ct values were determined by Rotor Gene 6 software.
The SABioscience gene expression PCR array was used with cDNA which was synthesized
from Qiagen purified RNA. After dilution (1:5) each 1 µl cDNA together with water and
SybrGreen Mix was placed per well, as recommended by the manufacturer. Roche Light
Cycler software determined Cp values automatically and results were normalized to HPRT.
ChIP-DNA and input DNA were used as template for quantification of H3K27me3 enrichment
at certain genomic regions. Each 1 µl of template DNA was mixed with 10 µl 2x SybrGreen
Mix, 8.5 µl water and each 0.25 µl of 100 pM primers. All reactions were carried out as
duplicates in the Corbett Rotor Gene RG 3000 real time cycler with the following PCR
program: 95◦C 15 min, 40x (95◦C 10 s, 60◦C 20 s, 72◦C 30 s, 80◦C 20 s), 50◦C 1 min,
67◦C to 95◦C with 0.5◦C temperature increase per 5 s. Ct values were determined by Rotor
Gene 6 software. Analyses were referred to non-precipitated input DNA by the delta-delta
Ct calculation.
Western blot
Protein samples were prepared from 1 · 106 cells which were washed at least twice in PBS
to clean from FCS protein contamination. The cells were lysed in 100 µl protein lysis buffer
and sheared by passing through a 21 gauge needle several times. Samples were heated up to
95◦C for 5 min and proteins were separated by SDS-PAGE in 10% SDS gels. Proteins were
next blotted onto nitrocellulose membranes followed by 30 min blocking of unspecific binding
sites in 5% milk in PBS 0.1% Tween20 at RT. Primary antibodies were incubated over night
at 4◦C in 1% milk PBS 0.1% Tween20 with the membrane. After three washes secondary
HRP-coupled antibodies were incubated for 2 h at RT in PBS 0.1% Tween20, before proteins
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were detected by ECL addition and chemiluminescence measurement, either by X-ray film or
by Biorad Imaging system. Membranes were stripped from antibodies by 30 min incubation
with stripping solution at 56◦C.
HDAC activity assay
Nuclei of unfractionated or MACS-separated BM cells were prepared by first incubating the
cells in a buffer containing 10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA
and 2.5 mM DTT, followed by lysis in 0.5% NP40. Nuclear proteins were then extracted
with a buffer containing 20 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EDTA and 2.5 mM
DTT. Equal amounts of nuclear protein extracts from unfractionated, Lin+ or Lin−/int cell
populations were subjected to HDAC enzymatic activity measurement using a fluorimetric
assay kit according to the manufacturer’s instructions. For analysis, triplicates of nuclear
extracts from the different cell populations were incubated with fluorochrome-conjugated
substrate. The release of fluorochrome as a measure of HDAC activity was quantified in a
fluorimeter with an excitation wavelength of 360 nM and detection of emission at 440 nM
wavelength. As a control, nuclear extracts of unfractionated BM cells were treated with 4 µM
TSA for 60 min prior to HDAC activity measurement, as recommended by the manufacturer.
HDAC activity assays were done with the help of V. Hornich and A.M. Mu¨ller.
7.2.4 Flow cytometry
All flow cytometric analyses were done on a BD FACS Canto I using FACS Diva and FlowJo
software.
Surface staining
For the detection of cellular surface antigens on living cells, approx. 2 · 105 cells were needed
and washed once in 1 ml of FACS buffer before staining.
For SSEA1 detection: ES or EB cells were incubated with 0.25 µl of mouse SSEA1 in 100 µl
FACS buffer for 20 min at 4◦C, washed once in 1 ml of FACS buffer, incubated for 20min
with anti-mouse Cy3 diluted 1:200 in FACS buffer and washed before analysis. BM cells
were stained for their LKS immunophenotype by first blocking Fc-receptors with a specific
monoclonal antibody for 15 min. Lin markers were bound by biotin-labelled rat antibodies
against CD4, CD8, Mac1, Gr1, B220 and Ter119 which were incubated together with the
cells for 20 min at a concentration of 0.25 µl per antibody in 50 µl FACS buffer at 4◦C. Cells
were washed twice in order to remove as much unbound biotin-labelled antibody as possible
and subsequently incubated with 0.1 µl streptavidin-PE-Cy5, 1 µl anti-Sca1-PE and 1 µl
anti-cKit-FITC in 100 µl FACS buffer for 30 min at 4◦C. After a final wash BM cells were
analyzed.
Chromatin flow cytometric protocols
Two different protocols were used to intranuclearly stain histone modifications for flow cy-
tometry:
In protocol A, modified from a Flow FisH protocol [194], cells were resuspended in 300 µl
freshly prepared flow FisH buffer and incubated for 10 min at 80◦C. Cells were allowed to
cool down to RT. After centrifugation (960x g) and removal of the supernatant, transparent
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cell pellets were resuspended in 200 µl PBS and cells were transferred into a FACS tube con-
taining 1 ml PBS. Next, cells were pelleted again and washed successively in PBS and FACS
buffer. As the fixation procedure does not allow prior cell surface immunofluorescent staining,
cell surface staining was performed together with intranuclear staining. For SSEA1/histone
modification-specific immunofluorescent stainings, first, 0.1 µl mouse anti-SSEA1 primary an-
tibody was added to cells in 100 µl FACS buffer. Cells were incubated for 20 min at RT. After
washing with 1 ml FACS buffer, a secondary anti-mouse-Cy3 antibody (1/200) was added
and incubated at RT for 20 min. Following repeated washes, histone modification-specific
antibodies or a rabbit polyclonal isotype control were added at the indicated concentrations
(Table 5.1) in 100 µl FACS buffer and incubated for 1 h at RT. The cells were then washed
twice in 1 ml FACS buffer and incubated with appropriate secondary antibodies for 45 min at
RT. For single stainings of histone modifications, anti-rabbit-PE (1/500) or anti-mouse-Cy3
(1/200) antibodies were used. For 2-color analysis, anti-rabbit-Cy2 antibody (1/200) together
with anti-mouse-Cy3 antibody (1/200) were used. After immunofluorescent staining, the cells
were washed in 1 ml FACS buffer and resuspended in 120 µl FACS buffer for analysis.
In protocol B, cells were resuspended in 100 µl fixation/permeabilization buffer (formaldehyde
basis; eBioscience) and incubated for 10 min at RT. Next, cells were pelleted (960x g) and
washed once in 200 µl permeabilization buffer (saponin basis; eBioscience) before incubating
with primary histone modification-specific antibodies in 100 µl permeabiliza- tion buffer for
1 h at RT at the indicated antibody concentrations (Table 5.1). Cells were spun down and
washed twice in 200 µl permeabilization buffer. Next, appropriate secondary antibodies were
added to 100 µl permeabilization buffer, and the cells were incubated for 45min at RT. Finally,
the cells were washed once in permeabilization buffer, transferred to FACS tubes, washed with
FACS buffer and resuspended in 120 µl FACS buffer for analysis. As formaldehyde-based fixa-
tion does not cause antibody or fluorochrome degradation, surface immunofluorescent staining
was done prior to fixation. Fixation in self-prepared 4% formaldehyde solution and perme-
abilization in 0.1% saponin also gave a successful staining outcome, but yielded lower signal
intensities.
AnnexinV apoptosis detection
Frequencies of living and apoptotic cells were analyzed by an Apoptosis detection kit. Ap-
prox. 2 · 105 freshly harvested cells were washed once in 1x binding buffer and were incubated
for 15 min at RT with 5 µl AnnexinV-FITC in 100 µl 1x binding buffer. Immediately cells
were analyzed.
Cell cycle analysis
To stain and analyze DNA content, 2·105 feeder-free ES cells were fixed in 70% ice cold ethanol
for at least 30 min at −20◦C. Following 2 washes in PBS, cells were incubated for 30 min
in 200 µl PBS with 100 µg/ml RNase and 50 µg/ml propidium iodide at 37◦C. Immediately
cells were analyzed.
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7.2.5 Cell sorting and separating
FACS
In order to sort differentiated cells that had reduced Oct4-eGFP levels from a heterogeneous
3-day old EB population, a gate of GFP medium intensity excluding Oct4-eGFPhigh ES cells
was defined. With the kind support of Ch. Linden in the FACSort facility of the Department
of Virology and Immunology, University of Wu¨rzburg, cells were purely sorted and culture
could be maintained under sterile conditions. BD FACS Vantage cell sorter and Diva software
were used.
Sorted cells were re-analyzed at FACS Canto I with respect to Oct4-eGFP immediately after
sorting. All remaining cells were plated at different cell concentrations in 24 well plates onto
MEFs in standard ES cell medium. HDAC inhibitors TSA or VPA were only added for the
first 24 h of culture post sort and subsequently withdrawn. After 2, 4 or 6 days cells from
individual wells were washed with PBS, allowed to detach from the dish by trypsin treatment
and finally subjected to Oct4-eGFP flow cytometric analysis.
MACS
Magnetic cell separation was used to separate Lin+ from Lin− BM cells. For this purpose
freshly isolated BM cells were first incubated with the Lin cocktail antibodies (CD4, CD8,
Mac1, Gr1, B220, Ter119, all rat) followed by incubation with goat anti-rat micro beads.
According to the manufacturer labelled BM cells were passed through a magnetic field with
Lin+ cells remaining inside the column and with Lin− cells passing through. The purity of
MACS was controlled by subsequent flow cytometric analysis after a staining with anti-goat
biotin and streptavidin-PE-Cy5 and revealed that the Lin− fraction comprised 10-20% Lin−
and 80% Linint cells. Therefore I denotated them as Lin−/int cells. The Lin+ compartment
comprised 70% Lin+ and 30% Linint cells (see also Figure 5.6 B).
7.2.6 Microscopy
Immunofluorescence staining of ES cells
For immunofluorescent imaging of undifferentiated ES cells, first MEFs were plated onto
gelatin-coated round coverslips in 24 well plates and subsequently ES cells were transferred
onto the feeder cells. Usually 1 or 2 days later cells were washed twice in PBS and fixed by
4% formaldehyde for 10 min at RT. After another wash in PBS cells were permeabilized with
0.1% TritonX in PBS for 10 min at RT. DAPI or Hoechst 33258 was added for 5 min at a
concentration of 50 µg/ml in PBS. Cells were washed for 5 min in PBS, for 1 min in H2O and
finally the coverslip was inverted and placed on a drop of ProLong Gold mounting medium
on a glass slide.
Staining of H3K9me3 in the nuclei of wild type and EED KO ES cells was done with fixed
ES cell colonies on coverslips as explained above. After permeabilization the samples were
blocked with gelatin in PBS 0.1% TritonX for 30 min at RT and together with the antibody
incubated over night. Following washing in PBS 0.1% TritonX anti-rabbit-Cy2 was added
for 2 h and finally ES cell colonies were embedded as described above. Heterochromatin foci
were captured by deconvolution imaging of entire ES cell colonies and subsequently frequency
and size were analyzed by ImageJ software.
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EB sections
EBs from HD differentiation were collected and frozen in Tissue-Tek embedding medium.
Cryosections of 10 µm thickness were prepared and the sections were fixed by 4% formalde-
hyde. DAPI staining was subsequently done as described above, including permeabilization
with TritonX.
FRAP
In order to analyze the chromatin dynamics of wild type and EED KO ES cells, a linker
histone H1-eGFP construct was transfected into ES cells and bleached by laser scanning
confocal microscopy. The time for fluorescence recovery was measured.
First, 4 · 106 feeder depleted ES cells were transfected with 10 µg plasmid by electroporation
(Amaxa, mouse ES cell nucleofection kit). Transfected cells were plated on coverslips in
flexiPERM chambers onto a layer of MEF feeder cells. Flow cytometric analyses 1 day after
transfection revealed a transfection efficiency of not more than 10% and weak fluorescence,
suggesting a detrimental effect of too much H1 protein in ES cells. One day after transfection
cells were subjected to FRAP, which was performed at the imaging facility of the Rudolf
Virchow Center, Wu¨rzburg, by M. Becker and G. Harms. Nuclei were visualized by addition
of Hoechst 33342 (10 µg/ml) to the cells immediately before bleaching.
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